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Goal Conflict Specific Rhythmicity (GCSR) is a biomarker of an anxiety process based on 
Gray’s neuropsychological theory of anxiety. It provides an objective definition of anxiety, 
empirical measure for diagnosis, and aims to align classification with cause. GCSR 
discriminates patients from non-patients at a group level but not at the individual level that is 
required for clinical use. This thesis aims to improve the individual discriminability of the 
biomarker. GCSR is measured via electroencephalography (EEG) in the stop signal task 
(SST). (Shadli, Glue, McIntosh, & McNaughton, 2015) showed that GCSR is not consistent 
across the SST. GCSR fluctuation rate (GCSR-FR) is a measure of GCSR variation across 
the task. GCSR-FR may be a better summary of GCSR than the current method. In this study 
there were four groups based on patient status and a theoretically driven manipulation 
effectiveness (ME) factor. The non-patient effective manipulation group (NP-EM) has 49 
members, non-patient ineffective manipulation group (NP-IM) has 30, patient effective 
manipulation group (PEM) has 38, and the patient ineffective manipulation group (P-IM) has 
19. GCSR-FR was extracted from the SST in three GCSR frequency bands, 4 – 6 Hz (theta), 
7 – 9 Hz (low alpha), and 10 - 12 Hz (high alpha). The domain of GCSR-FR is 1 cycle per 
task to 16 cycles per task. The primary analysis revealed that patient factor differences in 
GCSR-FR in effective manipulation relative to patient factor differences in GCSR-FR in 
ineffective manipulation show a quartic (m or w shaped) pattern across the GCSR-FR domain 
in the theta and high alpha bands. The patient factor group differences in GCSR-FR that 
occur in effective manipulation groups but not in ineffective manipulation groups are good 
targets for refining patient status prediction and therein improving GCSR’s individual 
discriminability. We speculate that the quartic pattern occurs because of five unique trial 
strategies each preferentially aggregating in one of the four groups. The finding demonstrates 
that there is intra task variation in GCSR that traditional summaries are incapable of 
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Chapter 1: Introduction 
1.1 Classification and diagnosis – a problem in psychiatry 
Mental disorders need a better classification system and diagnostic tools (Insel et al., 2010). 
The current classification systems define disorders by lists of symptoms (DSM-V, 2013; ICD-
10, 2004); and so diagnoses are not based on biological causes. Symptoms are a poor basis for 
diagnosis of mental health disorders because symptoms do not align with the causes of mental 
disorders. A symptom of a mental disorder may have multiple biological causes and so may 
inaccurately indicate the associated disorder (Filiou & Turck, 2011). The mismatch between 
symptom-based classification and the biological causes of mental health disorders leads to 
rampant overdiagnosis and misdiagnosis (Insel, 2014). 
The mismatch between symptoms and causes in the current classification of mental 
disorders is reflected in treatment outcomes. Anxiety disorders are among the most common 
diseases in the western world (Simpson, Neria, Lewis-Fernández, & Schneier, 2010) (Kessler, 
Ruscio, Shear, & Wittchen, 2009). The treatment of anxiety disorders suggests it is mis-
conceptualized in the current classification system. One of the primary treatments of anxiety 
disorders are serotonin specific reuptake inhibitors (SSRI’s). SSRI’s are only an effective 
treatment for approximately half of anxiety disorder cases (Ballenger, 2000). This implies that 
the current anxiety disorder label may be heterogeneous in terms of biological cause. 
Approximately three quarters of anxiety disorder patients are diagnosed with a secondary 
disorder (Michael, Zetsche, & Margraf, 2007). In these cases SSRI’s tend to treat all of the 
comorbidities effectively (Dunlop & Davis, 2008). This suggests an underlying SSRI-
sensitive disorder that is present across multiple current diagnoses, including the anxiety 
disorder label.  
Symptom-cause mismatch leads to problems for treatment because of the difference in 
level at which causes of the disorder and symptoms occur. The biological cause of mental 
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disorders occurs at a neural level. Symptoms of mental disorders occur as macro-level (e.g. 
behavioural or cognitive) variables. Misaligning the classification of disorders with the cause 
of disorders is likely to be the cause of poor treatment outcomes. Basing classification and 
diagnostic systems at the level that disorders are caused will address symptom-cause 
mismatch. Moreover, defining mental health disorders at a neural level should be beneficial to 
treatment outcomes (Insel et al., 2010). 
Basing the classification of mental disorders at the neural level should be beneficial to 
the practice of psychiatry. Neurally based classification and diagnostic systems will supersede 
the current ones because they are objective and should improve treatment outcomes. 
However, determining the neural source of a mental disorder is very difficult (Cuthbert & 
Insel, 2013). Technology, ethics, and the immense complexity of the brain limits what today’s 
researchers can achieve with traditional biomedicine. 
1.2 – The argument for biomarkers – the basis of classification systems.  
Biomarkers are an alternate diagnostic tool that can aid in defining mental health problems at 
a neural level. Biomarkers of mental health disorders are derived at a level similar in scale to 
the neural level, e.g. genetic or electrophysiological. Because of this, symptom cause 
mismatch  has less potential to affect disorder classification based on biomarkers. When 
classification and diagnosis of mental disorders is aligned with the cause of them, the 
treatment of them improves (Insel et al., 2010).  
The Biomarkers Definition Working Group defined a biomarker as;  
‘A characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention.’ (Atkinson Jr et al., 2001) 
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 The National Institute of Mental Health (NIMH) initiated research on a biomarker 
based classification system in 2010. The Research Domain Criteria (RDoC) is this framework 
for research established by the NIMH. Its purpose is to direct the development of a system 
that objectively classifies mental disorders (Insel et al., 2010).  
The DSM and ICD classification systems are impeding the progress of a biomarker-
based system (Cuthbert & Insel, 2013). Prior to the RDoC, research was limited to the 
disorders outlined by the current classification systems. The RDoC supports researchers in 
conducting mental health research outside the bounds of the current nosology. This is 
beneficial because it enables research to identify biomarkers of mental problems without the 
inaccuracy imposed by the current classification system. The current system is not the only 
obstacle to the development of a biomarker based classification system.       
1.3 - The basis of a biomarker.  
Biomarkers are difficult to derive because they aim to measure mental disorders which 
themselves are difficult to define. Furthermore, identifying a neural correlate of a mental 
disorder is an even more challenging endeavour (Cuthbert & Insel, 2013). To ensure the 
objectivity of a biomarker researchers need to resolve both of these issues.   
Neuroscientific theory is the best basis for a biomarker that is available to researchers. 
The past century has seen the rise and success of the biomedical approach to health research. 
Identifying the neurophysiological source of mental disorders using the biomedical approach 
would be the best option on which to base a biomarker. Unfortunately, it is not available to 
mental health researchers. The neural complexity of mental phenomena and ethical 
constraints prevent the use of direct neurophysiological observation and manipulation as 
investigative tools. Thus, neuroscientific theories for the neural mechanisms of mental 
phenomena are the best remaining alternative on which researchers can base biomarkers.  
4 
 
In the absence of reliable disorder constructs, the neuroscientific theory should define 
the disorder it is explaining. Thus, good theories on which to base a biomarker are those that 
explain the aetiology of the phenomena they describe, are empirically grounded, and are 
based at a biological level. An explanation of the aetiology of the mental phenomena 
contributes to the reliability of the definition the theory provides. Empirical grounding 
provides a high degree of objectivity in assessing the validity of the theory. A biological 
theory is preferable because it aligns with the level of the cause of the disorder. When this 
happens the classification of disorders is much less likely to suffer from misattribution like 
current disorder definitions. Using a biological theory prevents this issue effecting the 
subsequent biomarker, and by extension the disorder it identifies.  
1.4 – Anxiety disorders. 
As previously stated (chapter 1.1), anxiety disorders are some of the most common mental 
health diagnoses in the western world with prevalence estimates at 3.8 - 10.4% and 4.8 – 
10.9% worldwide (Remes, Brayne, Linde, & Lafortune, 2016) (Baxter, Scott, Vos, & 
Whiteford, 2013). The 2006 New Zealand mental health survey found the prevalence of 
anxiety disorders to be 14.8% (Browne, Wells, & Scott, 2006). 
 1.4.1 – Defining anxiety disorders – the mental health problem. 
Because of the high prevalence, anxiety disorders are a good target for biomarker 
development. Given that the current anxiety disorder label is heterogeneous, narrower 
definitions are required for the development of biomarkers. Gray’s Neuropsychological 
theory of anxiety provides one such solution (Gray & McNaughton, 2000).  
1.5 - Gray’s Neuropsychological theory of anxiety.  
Gray’s Neuropsychological theory of anxiety defines anxiety pharmacologically (Gray & 
Mcnaughton, 2000), via sensitivity to all clinically anxiolytic drugs. There are two main 
classes of clinically anxiolytic drug, classic and novel anxiolytics. Collectively, they do not 
share any effect other than an anxiolytic one.  
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1.5.1 – The pharmacological isolation of anxiety. 
Clinically active classes of anxiolytic drugs span multiple mechanisms of action including; 
5HT1a agonists, GABAa agonists, and Calcium Channel blockers. Comparison across these 
drugs can isolate an anxiolytic effect independent of action mechanism (McNaughton & 
Zangrossi, 2008). Gray’s theory is based on behavioural and neural responses that are 
exclusively sensitive to this isolated anxiolytic effect. Buspirone - a 5HT1a agonist, triazolam 
- a GABAa receptor complex agonist, and pregabalin - a VGCC blocker are the specific drugs 
used to triangulate the anxiolytic effect in this introduction (section 1.6).   
Gray’s theory is that the key effect underlying response to the isolated anxiolytic 
effect is reduced activity of the behavioural inhibition system (BIS) (Gray & McNaughton, 
2000). The BIS has several outputs including increased arousal, increased attention, and 
behavioural inhibition. The isolated anxiolytic effect reduces these outputs, leading to no 
increase in arousal, no increase in attention, and delayed behavioural inhibition. Behavioural 
inhibition is the best output of the BIS by which to measure the effect of anxiety. It has a clear 
behavioural definition making it an empirical measure, and does not occur as a result of other 
processes, as reductions in attention and arousal do. 
1.5.2 - Behavioural inhibition 
Behavioural inhibition is the suppression of prepotent behaviour. It occurs in response to 
conflict between biological goals. Directed behaviour occurs in response to these goals. Two 
primary types of directed behaviour are approach and withdrawal. Approach behaviours occur 
in response to appetitive situations whereas withdrawal behaviours occur in response to 
potentially threatening situations. Biological goals include hunger, sex (both appetitive), 
danger, and loss of resources (both aversive). A rat will move toward an opportunity to feed, 
and move away from a nearby cat. In proximity to both food and a cat, it needs a way to 
manage the level of threat, whilst investigating the potential to eat. This situation is an 
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example of an approach - avoid conflict. Conflict is most easily understood in this approach 
avoid case: but also occurs with approach–approach and avoid–avoid conflicts.  
In approach-avoid conflicts organisms employ defensive approach to investigate the 
situation. The organism will begin tentatively approaching the appetitive goal (e.g. food) 
while remaining on high alert for more information about the threat. As it gets closer to the 
threat, the increased sense of danger (threat cues) will lead it to decide that the food is not 
worth potentially being eaten. Behavioural inhibition then reduces the approach toward the 
food, leaving the drive to avoid the predator as the primary influence on behaviour. When the 
rat gets to the point where the cat is too close for comfort, behavioural inhibition stops it 
moving toward the food. An alternate system then moves it away from the cat as fast as it can. 
One type of directed behaviour (approach) is inhibited, to allow the other more salient drive to 
direct behaviour (avoidance).  
All anxiolytic drugs reduce behavioural inhibition (Gray & McNaughton, 2000). In a 
defensive approach example, a rat under the influence of an anxiolytic drug will approach 
toward food when there is also shock much further than a rat that is not. Behavioural 
inhibition has been reduced by the anxiolytic drug and so approach behaviour will not be 
stopped until later than usual. The rat will need to experience much greater threat cues before 
it becomes salient enough to engage the blunted BIS and stop approaching the food.    
1.5.3 - Rhythmical Slow Activity (RSA) 
RSA underpins Gray’s theory of anxiety. It is the rhythmic firing of the hippocampus (HPC) 
at 4 – 10 Hz. In the rat literature (where the terminology originates), the 4 – 10 Hz range 
overlaps with human theta (4 – 7 Hz) and alpha (9 – 12 Hz) bands. RSA occurs in all 
mammalian species, including humans (Sano, Mayanagi, Sekino, Ogashiwa, & Ishijima, 
1970). It is one of the most widely studied outputs of the hippocampus.  
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 RSA is exclusively sensitive to the isolated anxiolytic effect (McNaughton & 
Sedgwick, 1978) (McNaughton, Kocsis, & Hajos, 2007). All clinically active anxiolytic drugs 
decrease RSA frequency. No non-anxiolytic drugs have been found to decrease RSA 
frequency over the previous 40 years of testing (Gray & McNaughton, 2000). Thus, RSA is 
exclusively sensitive to clinically anxiolytic drugs. Gray and McNaughton, (2000) conclude 
that RSA is a neural process that is linked to clinical anxiety. 
1.5.4 – RSA and behavioural inhibition. 
RSA and behavioural inhibition are both exclusively sensitive to the isolated anxiolytic effect 
(Gray, & McNaughton, 2000). This demonstrates the link between RSA and behavioural 
inhibition. It is supported by two key findings. Firstly, RSA change is linked to the effect of 
anxiolytic drugs on behavioural inhibition. In Woodnorth and McNaughton (2002) fixed-
interval 60 sec schedule (FI60) responding (the approach goal) was inhibited by the absence 
of reward (the withdrawal goal). When an anxiolytic drug, specifically a benzodiazepine 
(BZD) was administered FI60 responding continued when the reward was absent. The 
inhibition of responding did not occur when the rat was under the influence of the BZD. RSA 
frequency decreased with the administration of the BZD and concurrently, the continuation of 
responding without reward. The co-sensitivity to anxiolytic intervention confirms the link 
between behavioural inhibition and RSA.         
 Secondly, (McNaughton, Ruan, & Woodnorth, 2006) shows that RSA mediates 
behavioural inhibition. This is confirmed by showing that the artificial replacement of RSA 
restores behavioural inhibition. They used a variety of anxiolytics to block hippocampal input, 
which prevents RSA. Preventing RSA stopped early learning in the Morris Water Maze 
(MWM). Behavioural inhibition is considered a key element involved in early learning in the 
MWM (Gray & McNaughton - ch 4.9, 2000). It is inferred that preventing RSA prevents 
behavioural inhibition. Critically, McNaughton, Ruan, & Woodnorth (2006) further show that 
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the artificial replacement of RSA at 7.7Hz reverses the anxiolytic effect on early learning in 
the MWM. The artificial re-establishment of RSA re-enables behavioural inhibition. These 
findings lead to the conclusion that RSA is, if not the direct neural cause of behavioural 
inhibition, at least a critical part of the neural process does. 
1.5.5 - The Behavioural Inhibition System (BIS) 
The BIS is the collective set of neural networks that work to enable behavioural inhibition. At 
the neural level the BIS is defined pharmacologically, by sensitivity to anxiolytic drugs. The 
work of Gray & McNaughton, (2000), presents the BIS, classifies the input that activates it, 
and explains the mechanisms via which it acts. The BIS is one of three neurological systems 
posited in reinforcement sensitivity theory (RST) that are outlined in (McNaughton & Corr, 
2004). The other two are the behavioural activation system (BAS) which is activated in 
appetitive situations, and the second is the fight, flight, freeze system (FFFS) which is 
activated in threatening situations. The RST differentiates the BIS as the system responsible 
for anxiety (defensive approach), and FFFS as the system responsible for fear (defensive 
withdrawal.  
The BIS is activated by goal conflict, i.e. when the drive toward food (approach) and 
the drive away from a potential predator (avoid) result in conflicting impulses. Approach and 
avoid are biological classifications of goal types. Two conflicting goals can be of either type, 
approach-approach, approach-avoid, or avoid-avoid. At a behavioural level conflict can be 
generated by signals of punishment, the absence of expected reward – e.g. non-reward of the 
FI60 schedule in Woodnorth & McNaughton, (2002), innate anxiety stimuli – e.g. the 
potential presence of a cat novel stimuli, and novel stimuli (Gray & McNaughton - fig 1.1, 
2000). 
The BIS resolves goal conflict via a variety of mechanisms (Gray & McNaughton - fig 
1.1, 2000). Behavioural inhibition occurs, halting the current behaviour. Arousal increases to 
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prepare the organism for future action and attention also increases to enable greater threat 
vigilance. The BIS resolves the conflict by increasing the valence of negative goal outcomes. 
From an ethological perspective, the capacity to manage conflicting drives would have 
been an extraordinarily advantageous, because it allows for defensive approach. For these 
organisms, threat from a predator was more dangerous than missing an opportunity to eat. For 
this reason, avoidance directed behaviour was dominant in conflict situations. They missed 
opportunities to capitalize on conflict situations where the food was far away enough from the 
predator. The advent of the BIS enabled organisms to gain a competitive advantage in these 
situations, allowing rudimentary organisms to forage for resources even under the potential 
presence of predators.      
Gray’s neuropsychological theory of anxiety provides an objective definition of 
anxiety that is indubitably supported by extensive pharmacological testing (Gray & 
McNaughton, 2000). The theory is derived at the biological level so it aligns with cause of the 
mental disorder. A biomarker based on Gray’s theory will not suffer the misattribution that 
plagues current disorder definitions. For these reasons, Gray’s theory of anxiety is a suitable 
theory on which to base a biomarker that can contribute to the RDoC’s goal of objective 
definition, classification, and diagnosis of mental disorders.  
Neo, Thurlow, and McNaughton (2011), initiated the development of a human 
biomarker based on Gray’s theory of anxiety. RSA is already a biomarker of the BIS and 
anxiety as defined by Gray (Woodnorth & McNaughton, 2002) but ethical constraints prevent 
its use as a human biomarker. Because everyday intracranial electrophysiology in humans is 
unethical, a cortical version of the biomarker was adopted. HPC RSA can be phase locked 
with medial frontal theta rhythmicity across a variety of behavioural tasks (Siapas, Lubenov, 
& Wilson, 2005) (Young & McNaughton, 2009). Thus, Neo, Thurlow, & McNaughton (2011) 
10 
 
chose to pursue a frontal cortical homologue because it may also be sensitive to anxiolytic 
drugs, and therein be a valid biomarker of the BIS.  
1.6 - Goal Conflict Specific Rhythmicity; an anxiety process biomarker  
Goal Conflict Specific Rhythmicity (GCSR) is a human homologue of the rat literatures RSA 
(Neo, Thurlow, & McNaughton, 2011) (McNaughton, Swart, Neo, Bates, & Glue, 2013). It is 
based on Gray’s neuropsychological theory and uses goal conflict conditions (nominally 
approach vs avoid) to activate the BIS. The 4 – 12 Hz rhythmicity is measured at frontal 
cortical sites via electroencephalography (EEG). The rhythmicity range is extended upward 
because RSA (4 – 7 Hz) is known to extend upward to the 9 – 12 Hz alpha band in humans 
(Miller, 1991 as cited in Neo, Thurlow, & McNaughton, 2011). Anxiety specific rhythmicity 
is isolated by contrasting high and low conflict EEG power.  
GCSR measured in motor inhibition tasks is sensitive to anxiolytic drugs 
(McNaughton et al, 2013) (Shadli et al, 2015) (Shadli, Smith, Glue, & McNaughton, 2016) 
(Shadli, High, Byers, Gibbs, Steller, Glue, & McNaughton, 2019). Shadli et al, (2015) found 
GCSR was reduced between subjects by buspirone (10mg), triazolam (0.25mg), and 
pregabalin (75mg), McNaughton et al, (2013) found it to be reduced by buspirone (10mg) and 
triazolam (0.25mg), and Shadli et al, (2019) found it to be reduced by buspirone (10mg) and 
pregabalin (75mg). These drugs were chosen to isolate the anxiolytic effect, therein showing 
GCSR to be sensitive to anxiety as defined by Gray’s theory.  
GCSR has not yet been shown to be exclusively sensitive to anxiolytic drugs as RSA 
has. Because GCSR mimics the behavioural conditions that RSA is sensitive to it is expected 
that it will also be exclusively sensitive to anxiolytics. However, without experimental proof 
that it is the case, it remains simple conjecture. It is also a necessary step to provide full 
support for its basis in Gray’s theory.   
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GCSR is also correlated with trait anxiety. The Spielberger Trait Anxiety Inventory 
(Spielberger & Gorsuch, 1983) measures trait anxiety as a predictor of anxiety disorder 
vulnerability (as defined by the DSM V). Despite their heterogeneity, some degree of 
correlation with anxiety disorders is expected. All reports of GCSR confirm this, having 
found significant correlation of GCSR with the STAI (Neo et al., 2011) (Neo & McNaughton, 
2011) McNaughton, 2013; Shadli et al, 2015; Shadli et al, 2016; Shadli et al, 2019). This 
provides additional support to the claim that GCSR is also a valid human biomarker of 
anxiety.  
1.7 - GCSR and motor inhibition.  
GCSR is primarily extracted from motor inhibition paradigms. It is most often refined in the 
Stop Signal Task (SST) by Neo et al, (2011) and has subsequently been derived from the 
Anticipatory Response Inhibition Task (Shadli et al, 2019). GCSR has been verified by 
anxiolytic sensitivity in both paradigms (Shadli et al, 2015; Shadli et al, 2019). In motor 
inhibition paradigms, GCSR is measured at the F8 electrode (int. 10 – 20) because motor 
inhibition is localised to the right inferior frontal cortex (rIFC) (Aron, 2011).  
 Motor inhibition tasks invoke a variety of motor processes. The motor inhibition 
process needs to be isolated from these. To isolate motor inhibition rhythmicity, the GCSR 
measure includes a contrast of stop processes and go processes. There are two primary types 
of trials in motor inhibition tasks; stop trials and go trials. Go trials require participants to 
make a choice in response to a two-option go stimulus (left arrow vs right arrow). Stop trials 
are identical to go trials, except that a stop signal occurs after go stimulus onset. After the stop 
signal participants must then attempt to inhibit their response to the go stimulus. To control 
for the rhythmicity associated with any general aspect of performance go trial rhythmicity is 
subtracted from stop trial rhythmicity. Thus, any remaining rhythmicity must originate from 
the processes specific to processing and responding to the stop signal. 
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1.7.1 - The horse race model. 
Motor inhibition tasks are good paradigms for eliciting GCSR because they impose goal 
conflict. Goal conflict is required because Gray’s theory suggests that the behavioural 
response to anxiety (behavioural inhibition) is only elicited in goal conflict situations. The 
primary model of motor inhibition is the horse race model (Logan & Cowan, 1984). The 
Horse Race model proposes that two independent, parallel processes (go and stop processes) 
are simultaneously active during motor inhibition. The otherwise separate processes meet at a 
single junction, where the stop process can halt the go process. If the go process passes the 
junction before the stop process then the act will proceed regardless of the stop process and 
motor inhibition will have failed. The go process corresponds to the approach and the stop 
process corresponds to avoid. Thus, the simultaneous parallel processes’ of the Horse Race 
model provide the neural basis for observing goal conflict.  
1.7.2 - The neurophysiology of motor inhibition.     
Motor inhibition networks support multiple forms of stopping.  The non-selective ‘hyper 
direct’ circuit that skips the right frontal cortex (RFC) globally inhibits motor activation 
(Nachev, Kennard, & Husain, 2008). A slower, selective ‘direct’ circuit involves the lateral 
RFC and enables inhibition of a specific motor activation without impeding other motor 
activation (Nachev, Kennard, & Hussain, 2008). Both circuits modulate the go process (as per 
the horse race model) via the pre Supplementary Motor Area (pre-SMA) (Nachev, Rees, 
Parton, Kennard, & Husain, 2005).  Refer to figure 1.1 (end of section 1.7.2) for illustration of 
these processes. 
The right inferior frontal cortex (RIFC) is implicated in SST based stopping. (Aron & 
Poldrack, 2006) used blood oxygen level dependant (BOLD) fMRI to observe RIFC response 
to the different SST trial outcomes. The percentage signal change of BOLD response for 
successful stopping (~6%) and unsuccessful stopping (~7%) were both greater than go trial 
percent signal change (~0%). Aron & Poldrack’s  findings suggest that the right frontal 
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cortical activity specifically contributes to the stopping process, irrespective of the outcome of 
a trial. 
Aron, Fletcher, Bullmore, Sahakian, and Robbins (2003) examined the impact of 
frontal cortex lesions on response inhibition in a stop signal procedure. Stop Signal Reaction 
Time (SSRT) is an estimate of inhibitory speed in stop signal tasks (Verbruggen & Logan, 
2008). Lesions to the rIFG (a subsection of the RIFC) significantly correlated with longer 
SSRT (i.e. slower response inhibition). Thus, implicating the rIFG specifically in motor 
inhibition. Their findings support the conclusion of (Aron & Poldrack, 2006) that the RIFC is 
responsible for motor inhibition specifically. 
Floden and Stuss (2006) used an altered SST which required rapid motor inhibition. 
Rapid inhibition in this task recruits the hyper-direct stopping mechanism (Garavan, Ross, 
Murphy, Roche, & Stein, 2002). In this task, lesions to the rIFG were not related longer 
SSRT’s (Flodden & Stuss, 2006). This suggests that the rIFG is part of the slower, ‘direct’ 
stopping circuit but not the fast ‘hyper direct’ stopping circuit, as was asserted in Nachev, 
Kennard, & Hussain, (2008). Flodden and Stuss suggest the procedure of Aron et al, (2003) 
permits participants to slow their go response in order to increase their chance to catch the 
stop signal in time. A motor inhibition task that prevents this strategy (such as that of Floden 
& Stuss), does not engage the rIFG-based, direct stopping mechanism. 
Aron’s SST does not prevent the recruitment of the cortically based direct stopping 
mechanism. This type of stopping can be measured by EEG at the rIFG as in Aron, et al, 
(2003). For this reason Neo et al’s, (2011) work used Aron’s SST as the task to elicit GCSR. 
It allows the cortical response to goal conflict - as part of the horse race model to be 
measured. Neo et al, (2011) found significant GCSR across the 4 – 12 Hz band, which lead 
them to suggest that the BIS influences the direct motor inhibition network at the right 
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inferior frontal gyrus (rIFG). Figure 1.1 shows the model they propose. As the BIS is defined 
pharmacologically, the later findings of McNaughton, (2013), Shadli et al, (2015), and Shadli 
et al, (2016) that GCSR is anxiolytic sensitive, supports Neo et al’s claim. Furthermore, 
Shadli et al, (2019) used an alternate motor inhibition task that prevents the use the hyper-
direct stopping mechanism. They also found significant GCSR, and verified it with anxiolytic 
drugs. 
 
Figure 1.1. Copied from Neo et al, (2011) showing the updated model of motor inhibition networks. In 
accordance with the horse race model (Logan & Cowan, 1984), the go and stop processes are shown. 
They meet at a single junction in the sub-thalamus. Three stopping processes include the hyper-direct 
(fast) circuit, direct circuit (slow), and a new (slower), BIS based stopping mechanism. For review of 
motor inhibition networks see Nachev, Kennard, and Hussain, (2008).     
1.8 - GCSR and the Stop Signal Task. 
GCSR requires the manipulation of goal conflict to measure anxiety. Goal conflict in the SST 
is manipulated by altering the stop signal delay (SSD). The SSD is the delay between the go 
stimulus onset and the stop signal onset. Variation in the SSD alters the difficulty of stop 
trials. A shorter SSD means the stop process begins earlier, and has a greater chance of 























of catching the go process. Figure 1.2 shows how the SSD and SSRT alter the probability of 
successful inhibition (Pinhibit).  
Shadli et al, (2015) modified the SST for the purposes of extracting GCSR. This SST 
includes three SSD lengths; short, medium, and long. The medium SSD is adjusted 
throughout the task to promote 50% accurate response inhibition, i.e. elicit maximum goal 
conflict. Medium SSD trials are the high conflict condition. Under these conditions, the stop 
and go process are equally likely to determine the outcome of the trial. The short SSD and the 
long SSD are low conflict conditions. Short SSD’s are avoid dominant because the probability 
of inhibition is high. Long SSD’s are approach dominant because the probability of inhibition 
is low.   
 
Figure 1.2. Figure copied from Aron et al, (2003) showing how the SSD affects the probability of 
successful inhibition. In the SST, goal conflict is manipulated by altering the SSD. Three SSD lengths 
(short, medium, & long) are used to contrast high and low goal conflict conditions. High goal conflict 
occurs in the medium SSD, which is adjusted to promote 50% response inhibition. Low goal conflict 
occurs in the short and long SSD’s, in which the probability of inhibition is high and low respectively. 
1.9 – Clinical utility of the biomarker. 
The current literature establishes GCSR as the first empirical biomarker of anxiety. It is 
capable of discriminating anxiety patients at a group level. Shadli, (2015, p. 125) concluded 
that GCSR is not yet valid at the individual level. To be useful as a diagnostic tool, 





The lack of individual discrimination primarily occurs because GCSR is a blunt 
measure. EEG cannot isolate the BIS contributions from other sources of rhythmicity. 
Contributions from other nearby systems and non-BIS motor inhibition processes are also 
included in its measurements. This is a low signal to noise ratio. Addressing the low signal to 
noise ratio is the best way to improve the individual discriminability of the biomarker.  
Directly improving the signal to noise ratio of GCSR is not feasible without intra-
cranial measurements of neural activity. In a clinical setting intracranial measurement is not a 
practical option. Thus, we need an alternative option for improving the biomarkers capacity to 
predict individual patients. This thesis aims to investigate a novel summary measure of GCSR 
and its suitability to improve patient status prediction.    
1.10 - GCSR fluctuation within the SST.  
The novel method of GCSR summary is based on the fluctuation of GCSR across the SST. 
Traditional investigations of GCSR have averaged GCSR either across the SST (Neo et al, 
2011; McNaughton, 2013; Shadli et al, 2019), or individually across the three blocks of the 
SST (Shadli et al, 2015; Shadli et al, 2016). This form of analysis is prominent because it 
addresses issues such as missing data, and cross task differences in strategy (such as 
attentional deficits). Averaging GCSR power across the task ignores the possibility of GCSR 
dynamics within the SST. Investigating GCSR fluctuation across the task may provide an 
avenue for refining individual discriminability. 
Shadli et al, (2015; 2016) segmented GCSR into three blocks across the SST. They 
both find significant GCSR in the first and third blocks, but not the second. This shows that 
GCSR is not consistent across the task. It further highlights that we are entirely unaware of 
full range of GCSR dynamics across the task. To begin investigating GCSR dynamics, a 
greater GCSR resolution is required. Trial by trial analysis of GCSR will provide the level of 
resolution required to investigate GCSR dynamics across the SST. The investigation of GCSR 
17 
 
dynamics is centred on identifying patient and non-patient group differences in magnitude of 
GCSR fluctuation. These may be able to be harnessed to improve patient status prediction and 



























Chapter 2: Methods 
2.1 Participants 
There were two samples in this thesis; non-patient and patient. The non-patient sample were 
recruited through a local employment website Student Job Search and via advertising on 
Facebook. The non-patient sample is comprised of two individual healthy participant groups 
that are combined in this study. A community control sample that were age and gender 
matched to the patient sample and a second non matched non-control sample. This sample is 
used in conglomerate for two reasons. The primary reason is to simplify further analyses by 
using only two samples (as opposed to splitting the non-patient group and using three groups 
overall). Combining the respective non-patient groups increases the sample size and 
subsequently the capacity to detect statistically significant differences in intra-task GCSR 
fluctuation. The second reason is so that this project does not overlap too closely with the 
work of another student in the laboratory.  
The patient sample was recruited via Facebook advertisements only.  The non-patient 
sample were paid $30 for their participation in the experiment, and the patient sample were 
reimbursed $40 to cover expenses such as travel. This experiment was approved by the 
University of Otago Human Ethics committee (Health: H 15/005). Table 2.1 shows the 
demographics of both the non-patient and patient samples. Julia McIntosh, Lynne Ando, and 
Tom Lockhart conducted the non-patient’s sessions, and Dr Shabah Shadli collected the 
patient data.  Dr Lisa Silva, Dr Kimberley Wake, and Julia McIntosh conducted the patient 
MINI interviews.   
 
Table 2.1. Demographic details for Non-patient and Patient groups.  
 N sex(M/F) 
Age 
(Mean±SD) handedness(L/R) 
Non-Patients 79 23/56 27.0 ± 8.6 4/75 





2.2.1 Task environment. 
The behavioural task was conducted in a body protected electrical area, as required when 
conducting any EEG study. A body protected electrical area is an electrically shielded area 
that complies with the combined Australian and New Zealand electrical safety standards 
AS/NZS 3200 - Medical electrical equipment General requirements for safety, and AS/NZS 
3003 - Electrical installations – Patient areas of hospitals. The monitors used to present the 
behavioural task and questionnaires were 59.9cm widescreen LCD monitors. Participants sat 
in office chairs approximately 1m from the screen and used the buttons on a standard 
computer mouse to respond. The SST is a uni-manual task, so participants use their dominant 
hand’s index and middle fingers to respond. 
2.2.2 Mini International Neuropsychiatric Interview (MINI) 
The Mini International Neuropsychiatric Interview (MINI) English version 6.0.0 (Sheehan et 
al., 1998) was used to assess the patient group. The MINI is a brief structured interview which 
aids in the diagnosis of major axis I disorders as described in the DSM-IV and ICD-10. The 
MINI is comprised of precise, closed questions. MINI questions address 15 diagnostic 
categories: Major Depressive Episode, Suicidality, Manic/Hypomanic episodes, Panic 
Disorder, Agoraphobia, Social Anxiety Disorder, Obsessive-Compulsive Disorder, 
Posttraumatic Stress Disorder, Alcohol and Substance Abuse/Dependence, Psychotic 
Disorders, Mood Disorder with Psychotic features, Anorexia Nervosa, Bulimia Nervosa, 
Generalized Anxiety Disorder, and Antisocial Personality Disorder.    
A clinical psychology trainee conducted the MINI. For every patient the interviewer was 
different from the experimenter. The interview was conducted in a private room. Patients 
were asked about all diagnostic domains. Table 2.2 shows the primary diagnoses of the 
patient sample. A majority of the patient sample were primarily diagnosed as Generalized and 
Social anxiety disorders. All of the patient sample scored above the cut-off for an anxiety 
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disorder (GAD or SAD). However, MINI procedure states that the disorder with the highest 
score is the given diagnosis (Sheehan et al, 1998). In accordance with this, we report the 
distribution of the primary diagnosis.    
Table 2.2. Distribution of the primary MINI diagnosis of the patient sample. 
MINI primary diagnosis n M/F 
Generalized Anxiety Disorder (GAD) 28 2/26 
Panic Disorder (PD) 2 0/2 
Social Anxiety Disorder (SAD) 3 0/3 
Social Phobia (SP) 7 1/6 
Post Traumatic Stress Disorder (PTSD) 3 0/3 
Major Depressive Episode (MDE) 2 1/1 
Anorexia Nervosa (AN) 1 0/1 
GAD & PD 1 1/0 
GAD & SP 2 1/1 
GAD & Alcohol Dependence 1 0/1 
GAD & PD & SP 2 2/0 
GAD & PD & PTSD 1 0/1 
PD with Agoraphobia 1 1/0 
PD without Agoraphobia  2 0/2 
SP without Agoraphobia 1 1/0 
 
2.2.3 Personality questionnaires 
All participants completed two sets of questionnaires, one prior to completing the behavioural 
task and a second after completing the behavioural task. The pre-task set of questionnaires 
included the Trait Anxiety scale items from the STAI (Spielberger & Gorsuch, 1983), the 
Extraversion and Neuroticism items from the EPQ-R (Eysenck Personality Questionnaire-
Revised; Eysenck & Eysenck, 1991), and the BIS items from the BIS/BAS scale (Behavioural 
Inhibition System/Behavioural Activation System; Carver & White, 1994). The post-task set 
of questionnaries included probe questions on sleep and depression history, and ten scales 
from the PID-5 (American Psychiatric Association, 2013) including the Depressiveness, 
Anxiousness, Emotional Liability, Perseveration, Separation Insecurity, Withdrawal, 
Anhedonia, Risk-taking, Intimacy Avoidance, and Restricted Affectivity scale items. 
Personality questionnaire results are not used in this thesis and therefore are not reported.  
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2.2.4 EEG recording 
EEG was recorded using Waveguard EEG caps (ANT Neurotechnology). Three cap sizes 
were used during data collection; small (c = 47 – 53cm), medium (c = 53-57cm), and large (c 
= 57-64cm). Recordings from the scalp were made using Ag/AgCl electrodes in the EEG 
caps. The electrodes were arranged in the international 10 – 20 arrangement. Data were 
recorded from 16 channels; F7, F3, Fz, F4, F8, T3, C3, Cz, C4, T4, T5, P3, Pz, P4, T6, and 
Fp1. The Fp1 electrode was used only to detect eye-blink artefact activity (see data 
processing). All electrodes were independent and re-referenced against the average of the A1 
& A2 mastoid electrodes.  
Electro-gel (Electro Cap International, USA) was inserted into each recording 
electrode using a 3ml syringe and Precision Glide 16 gauge blunt needle (Benton, Dickenson 
& Co, New Jersey, USA). Impedance measurements from the ASA Neurotechnology EEG 
machine were reduced to less than 20KΩ for task EEG recording. The EEG was sampled at 
256Hz with 1-36Hz band pass filters and was down-sampled to 128Hz for analysis. All 
recording occurred in certified body protected electrical areas in the Department of 
Psychology at the University of Otago.     
2.3 Procedure 
Participants met the experimenter at the University of Otago Psychology department (as 
arranged via email). The procedure along with any risks and ethical considerations were 
outlined.  They were given an opportunity to ask any questions they had and signed consent 
forms were obtained (see Appendix A for non-patient form, Appendix B for patient form).    
Patients were then administered the DSM-MINI interview (approx. 30 minutes). All 
patient data were stored confidentially. Post-experiment patients were referred to, identified, 
and coded only by participant number. Aside from these differences, the procedure for 
patients was identical to that of controls, as subsequently described.  
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All participants were led to a separate building where the main experiment was 
conducted. The height and weight of each participant was measured and recorded in SI units. 
The circumference of their head was also measured to ensure EEG cap fit, and mark Fp1 and 
Fp2 of the International 10:20 system. The pre-task questionnaires were then delivered. Pre-
task questionnaires typically required 10 minutes.  
Participants were then led to a body protected electrical area to complete the 
behavioural task (SST). The EEG cape was fitted and electrode impedances reduced. EEG cap 
setup took approximately 20 minutes to complete. Simple jaw clenching and blinking tasks 
demonstrated to participants how facial movement impaired the EEG recording. The 
experimenter requested that participants minimize facial and body movements during the task, 
but also conveyed that blinking was acceptable. The SST was then completed. The SST took 
approximately 30 minutes to complete. The SST used was written and presented by 
MATLAB. Similarly, responses, response timing and task cues were recorded via MATLAB. 
EEG caps were removed, and participants were given a chance to wash their hair 
before they returned to the questionnaire computer to complete post-experiment 
questionnaires. Post-task questionnaires required approximately 10 minutes to complete. 
Finally, participants received their respective payment or reimbursements and signed to 
indicate receipt of it.  
2.4 Stop Signal Task 
The Stop Signal Task (SST) is a response inhibition task similar to that used in Aron and 
Poldrack (2006). Neo et al, (2011) were the first to use the SST to elicit GCSR. However, this 
thesis uses the modified SST of Shadli et al (2015) which involves two structural 
modifications. Firstly, short and long Stop Signal Delays (SSD) were determined as a 
proportion of the participants mean go reaction time (ΜGoRT), whilst the intermediate SSD 
was tracked using a staircase like system to promote stop trial response-inhibition parity. 
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These changes are similar to those of (Carter et al., 2003). The specific calculation of these 
SSD’s is described later in this section. Secondly, there is feedback in the form of smiley and 
frowny faces after each trial to promote accuracy and response speed.  
The task is broken into four blocks, an initial practice block of 30 trials, and three 
subsequent blocks of 132 trials each. The practice block is comprised of go trials only. Each 
of the three subsequent blocks contain 99 go trials and 33 stop trials. There are 426 trials in 
total and 99 stop trials across the task. 
The purpose of the practice block was to familiarize participants with the task, and 
establish a participants MGoRT. The EEG data from the practice block was not analysed. 
Feedback was not given for practice block trials.  
The three main blocks are used to calculate GCSR. The structure (total number of 
each trial type) of each block is identical but the order of trials is unique to each block to 
counter balance the order of SSD’s. There are four trial types used to calculate GCSR; go 
trials, short SSD stop trials, intermediate SSD stop trials, and long SSD stop trials. Each main 
block contains 11 of each type of stop trial (short, intermediate, and long SSD’s), the 
remaining trials in each block are all go trials. Each stop trial is pseudo randomly placed 
within a 4-trial group. There is a 1 – 2 minute gap between the main blocks.  
Go trials are a simple choice reaction task (CRT) (Logan, 1994) (Logan, Cowan, & 
Davis, 1984). Our SST go trials began with the presentation of a white fixation circle on a 
black background. After 500ms a white arrow (the go stimulus) pointing right or left, 
appeared within the fixation circle. If the participant responded (regardless of accuracy), or 
alternatively following 1000ms with no response, the stimulus and fixation circle disappeared. 
After 500ms, the appropriate feedback was presented for 500ms. A 1000ms inter trial interval 
(ITI) separates each trial. Each trial lasted approximately 3500ms and the task.  
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Stop trials proceed in a similar manner to CRT go trials, with the presence of a 
1000Hz auditory tone as the stop signal. The stop signal occurs at one of three delay lengths 
(short, medium, or long) after the appearance of the go stimulus. The stop signal indicates to 
participants to inhibit their responses. The stop signal will sound for 500ms unless the 
participant fails to inhibit their response. The relevant feedback is presented for 500ms; a 
smiley face in the case where the participants inhibit their response or a frowny face if they 




Figure 2.1. Illustration of SST trials. Figure is a replication of the original in Shadli, (2015). Trials begin 
with a white fixation circle, and proceed to the simple CRT. Stop trials are differentiated from go trials 
by the presence of the auditory stop signal. Potential responses and corresponding feedback to the 















































The three SSD’s are calculated individually, short and long as a function of previous go trials, 
and the medium SSD via a staircase-like tracking system (Aron et al, 2006; Shadli et al, 
2015). The initial SSD’s are determined by the ΜGoRT of the practice block, the short SSD 
at 20%, medium SSD at 45%, and the long SSD at 70% of practice block ΜGoRT. After the 
first main block begins, the short and long SSD’s are calculated as 20% and 80% respectively 
of the ΜGoRT of the previous 16 Go trials. The medium SSD is adjusted from the initial 
value via the tracking system in increments of 30ms, as opposed to 50ms as in Aron & 
Poldrack (2006) and Neo et al (2011). In response to successful inhibition, the medium SSD 
is increased incrementally and vice versa, in response to failure of inhibition, decreased 
incrementally. The medium SST is restricted and cannot be within 50ms of the short or long 
SSD’s.  
2.5 Data processing 
2.5.1 Behavioural data 
Trial data were recorded for SSD, reaction time, response choice (left/right), and inhibition 
choice (success/failure). Two measures were calculated from these data, MGoRT and Stop-
signal reaction time (SSRT). MGoRT is the average delay between go stimulus onset and 
participants response. SSRT is a theoretically informed estimate of a participants stopping 
speed. SSRT is the difference of the median GoRT and the mean medium SSD.      
2.5.2 EEG data 
Artefacts were removed from the EEG data in three steps. Firstly, a simple 3-point running 
mean effectively provided a low pass filter at 43Hz to eliminate residual high frequency 
noise. Secondly, eye-blink artefacts were removed from the EEG recording via the methods 
described in (Zhang et al., 2017) leaving residual EEG. Finally, experimenter visual 
inspection detected any remaining artefacts, and these data were replaced across all channels 
with missing value markers. Missing EEG data result in missing GCSR data. The replacement 
of missing GCSR data is outlined in section 3.2.1. The methods of Zhang et al, (2017) remove 
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a least square error model of an eye blink based on the ballistic nature of the physiological 
components of an eye blink.   
Discrete frequency power values were extracted from 500ms window’s post stop 
signal, across the 4 – 12 Hz range (alpha and theta bands) using a Hanning window, and Fast 
Fourier Transform (FFT), followed by log transform to normalise error variance. A Hanning 
window is a cosine waveform which is applied at the centre of cosine wave stressing 
maximum power from the middle 50% of the window and minimum power from the outer 
50% of the window. A 1000ms Hanning window is applied to each trial starting 250ms before 
the stop signal. Thus, maximum power is extracted from the 500ms immediately post stop 
signal. Using a 1s Hanning window is preferable to a square 500ms window because it 
improves transform quality and doubles the frequency resolution. Discrete frequency power 
was extracted from the 500ms window by FFT. For go trials, power was extracted from an 
identical position in time within the trial to that of the adjacent stop trials stop signal. The 
power values are log transformed. A log transform stretches data smaller than 1 and 
compresses data which is larger than 1. The data was log transformed to normalize error 
variance. The resulting units of power are log(µV2).  
2.6 Statistical analysis 
2.6.1 Orthogonal polynomial contrasts 
GCSR is an orthogonal polynomial contrast of two factors (McNaughton, 2014). The first 
factor is a linear contrast of trial type (stop vs. go), which isolates the stopping specific 
rhythmicity by subtracting baseline go rhythmicity. The second factor is a quadratic contrast 
of SSD (medium vs. the average of short and long). The quadratic contrast isolates the 
conflict-specific medium-SSD condition’s rhythmicity from the low-conflict short and long 
SSD conditions rhythmicity. Using a quadratic contrast to isolate conflict specific rhythmicity 
precludes SSD length confounding the conflict specific factor, as would be the case in a linear 
contrast of short and medium, or medium and long SSDs.   
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Orthogonal polynomial contrasts can be tested within ANOVA (McNaughton, 1993) 
and represent the polynomial (linear, quadratic, cubic, etc) trends in the differences (contrast) 
between factor levels (e.g. time points, dosages, or SSD lengths). Because the contrasts are 
orthogonal, the technique can estimate a specific polynomial trend without the value being 
altered by other trends that contribute to the overall data pattern. Importantly, this also means 
that the contrast represents a particular shape within the bounds tested and not a function that 
can be extrapolated outside those bounds. 
2.6.2 Fast Fourier transform 
An FFT decomposes any complex signals into a discrete set of sine wave power values. For 
example frequency power values are extracted from the EEG signal by FFT. In this thesis an 
FFT was also used in a less conventional manner. Fluctuation in GCSR across the task was 
extracted from the series of trials for each GCSR frequency value. Because there are 33 
GCSR trials in the SST, the domain of the GCSR fluctuation output is 1 – 16 cycles per task. 
GCSR fluctuation magnitude is measured in (log(µV2))2. This method of extracting 
fluctuation from GCSR across the task was chosen because it measures the full range of 
potential fluctuation. As highlighted in section 1.10 two previous publications (Shadli et al, 
2015; Shadli et al, 2016) passively identified a single fluctuation across the task, but there is 
an entire range of potential fluctuations that are entirely un-investigated. Using an FFT as the 







Chapter 3: Results 
The absence of GCSR in block 2 in Shadli et al, (2015) shows that GCSR is not uniform 
across the SST. This may not be the only dynamic that is present in GCSR across the task. 
Investigating the full range of GCSR dynamics requires a finer grain measure of GCSR. 
GCSR is a composite measure based on six-values. In the SST each of these trials occurs once 
every twelve trials. From each set of twelve trials a ‘GCSR trial’ can be calculated. From this 
point onward, the term trial refers to a ‘GCSR trial’.  
There are eleven of these trials per block, and so thirty-three across the entire SST. 
These trials are the finest instance of GCSR. They allow for the complete investigation of 
GCSR variation across the task. The goal of this chapter is to develop appropriate means of 
displaying and analysing the data; resolve missing data issues that cause problems for such 
fine-grain analysis; and then report a series of analyses that progressively refine the results 
and so the conclusions that can be drawn from them. All analyses were conducted on the IBM 
SPSS statistics package, v25.  
3.1 - Spectrogram development 
To being our inspection, we needed to develop a way to visualize GCSR across the SST. 
Presenting GCSR across the SST requires a different approach than previous publications 
have employed because a line graph cannot show multiple instances of GCSR across the 4 – 
12 Hz frequency range. Our solution is to present GCSR on a spectrogram. On a spectrogram 
GCSR power can be measured by colour, while trial number is presented along the x-axis and 
the frequency range along the y-axis. 
To effectively present the full range of data a spectrogram needs an appropriate power 
to colour calibration. Figures 3.1 shows the distribution of both individual GCSR values and 
sample mean GCSR values. The non-patient and patient samples for both variables 
(individual values and sample mean values) are normally distributed and centred on similar 
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means. This allows a common power to colour calibration that effectively presents the range 
of data for both samples. Common power to colour calibration allows direct visual 
comparison between samples.    
 
Figure 3.1. Distribution of GCSR trial power for (A-C) all individuals across GCSR frequencies and 
trials, and (D-F) group means (all trials, all frequencies). A, D – patient group. B, E – non-patient 
group. C, F – both groups together, show the distribution of all individuals’ data. GCSR trial frequency 
values (for both individual and group mean datasets) are rounded to the nearest hundredth log 
microvolt squared. Non-patient and patient group datasets are all normally distributed.      
Figure 3.2 shows the power to colour calibration for individual and group mean GCSR 
spectrograms used in this thesis. Individual’s GCSR spectrograms have upper and lower 
bounds of 2 log(μV2) and -2 log(μV2). These bounds encompass 97.23% of the combined 












































0.4 log(μV2) and -0.4 log(μV2). These bounds encompass all of the non-patient and patient 
samples mean GCSR values. 
 
Figure 3.2. Power to colour calibration for A) individual GCSR spectrograms and B) group mean 
GCSR spectrograms. The upper and lower bounds of individual’s spectrograms are +2 log(μV2) and -2 
log(μV2). Values less than -2 log(μV2) will display as dark blue and values greater than +2 log(μV2) will 
display as dark red. The upper and lower bounds of group mean spectrograms are +0.4 log(μV2) and -
0.4 log(μV2). Values less than -0.4 log(μV2) will display as dark blue and values greater than +0.4 
log(μV2) will display as dark red.    
  
3.2 - Resolving the missing data issue. 
We began our analysis by looking at individual GCSR spectrograms. Immediately we 
encountered a missing data issue. Figure 3.3 shows the individual GCSR spectrogram of six 
representative non-patients and patients. The prevalence of missing data (shown in fig 3.3 as 
navy blue bars spanning the entire frequency band) completely prevents cross task analysis of 
GCSR.   
-0.4- 0.4+ 0-0.2 0.2
log (μV2)







Figure 3.3. Six examples of non-patient and patient, trial-by-trial GCSR across the 4 – 12Hz frequency 
range. Solid navy blue bars spanning the frequency range indicate missing GCSR data for that trial. In 
some instances, i.e. non-patient 7, this makes cross task analysis impossible.  
 
Missing data causes a greater issue when it is calculated on a trial-by-trial basis. Previous 
GCSR publications avoided this missing data issue by averaging each of the six trial types’ 
extant data across the task (or blocks) before calculating GCSR (Shadli, 2015). Because 
GCSR is a six-value composite measure the impact of missing data at for any of these values 
compounds as higher order components are calculated. Table 3.1 shows the proportion of 
single trials missing data and the impact on higher order components that they are a part of.  
Table 3.1. Proportion of non-patient and patient samples missing trial data. The impact of missing data 















 Trial type Stop signal delay Conflict Specific GCSR 
 Stop  Go  Short Medium Long Stop Go - 
Non - patients 7.8% 7.9% 3.1% 4.6% 16.0% 27.1% 27.4% 34.7% 
Patients 6.5% 6.1% 2.5% 3.8% 12.5% 28.3% 28.5% 35.1% 
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To solve this problem, a linear interpolation method was developed to estimate the single trial 
missing GCSR data. There are alternate methods that are preferable for some instances of 
missing data. Missing data can occur if a single EEG sample is missing but also if the entire 
trials EEG is impeded by an artefact (i.e. facial movements). In single sample instances the 
interpolation of the EEG sample prior to power extraction via FFT is a preferable method of 
replacement. Such replacement is impossible in artefact instances of missing data. Ultimately 
the current method was chosen because it is an appropriate solution for all types of missing 
data.   
3.2.1 – Data replacement method. 
Missing trial data were replaced with least-squared-error, linear interpolated estimates from 
adjacent trials in a frequency specific manner. The Matlab code (v25) to replace missing trial 
data is included in Appendix A. The missing data replacement method is illustrated in Figure 
3.4. In figure 3.3 there are some instances where multiple consecutive trials are missing (e.g. 
non-patient 7). In these situations, the replacement data are drawn from a larger number of 
adjacent trials. This ensures that consecutive missing trials are not estimated from a lesser 
number of adjacent points. 
 For n consecutive missing trials, missing data estimates were interpolated from the 
nearest n + 6 trials. Figure 3.4 panel C shows that these adjacent trials are drawn equally from 
either side of missing trials. When n is odd, there the adjacent trials cannot be equally drawn 
from either side (figure 3.4 panel B). In these instances, the greater number of trials were 
selected from before the missing trial(s). In some instances, missing trials may be too early in 
the SST to draw enough adjacent trials from before them. Vice versa, missing trials may be 
too late in the SST to draw enough adjacent trials from after them. In these cases, more 
adjacent trials are drawn from the available side.     
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As part of the missing data replacement, all participants were screened for excessive 
missing data. Each participant has 33 trial for each trial type and SSD (e.g. 33 medium SSD 
stop trials). If any participant were missing 17 or more trials from any of the trial type SSD 
length, they would have been removed from the sample. Fortunately, no participant from 




Figure 3.4. A) Mock trial power values (light grey) of 15 trials for a single frequency. Trials 7, 10, and 
11 (highlight by black arrows) are missing data. B) Trial #7 data (white bar) is estimated using least 
squares linear interpolation of the nearest 7 trials data (dark grey). Only a single trial is missing data, 
therefore the estimate is interpolated from an odd number - 7 adjacent points. They cannot be drawn 
equally from either side of the missing data point, instead 4 trials are drawn from before and 3 from 
after the missing data point. C) Trial’s #10 and #11 data (white bar) are estimated from using the same 
















































before and after the missing data are available to estimate the missing data. D) The 15 mock trial 
power values with the estimated replacement data in trials 7, 10, and 11.   
 
The six sample spectrograms in figure 3.4 are shown after replacement of missing data in 
figure 3.5. The figure shows the value of the data replacement. The spectrograms are 
complete, and suitable for cross task analysis. The data replacement method was applied to all 
the remaining participants, to complete a full dataset.   
 
Figure 3.5. Six examples of non-patient and patient, trial-by-trial GCSR across the 4 – 12Hz frequency 
range. Variation of GCSR across task and frequency appears random in both non-patient and patient 
groups.  
3.3 - Initial observations.  
3.3.1 - Individual spectrograms 
Figure’s 3.4 and 3.5 show that trial-by-trial GCSR on individual spectrograms is highly 
variable. For instance, previous publications have shown an inverted-U shape across the 
frequency range in some samples, (McNaughton, 2013; Shadli et al, 2015), but not in others 
















does not occur at the individual trial level, at which the frequency-by-frequency GCSR 
appears to be highly variable.  
To make use of the greater resolution of GCSR we looked for several types of GCSR 
feature that could occur at the individual participant level. These include general gradation 
patterns, or single trial events. Figure 3.5 shows that some of these patterns occur within an 
individual’s spectrogram. Unfortunately, no systematic pattern of GCSR across trials occurs 
in any participant’s spectrogram. Figure 3.5 also shows that there is no common pattern 
across individuals.   
3.3.2 - Sample mean spectrograms. 
The high level of inter-trial variability is not unexpected, given that GCSR is a six-component 
measure. Even small variations in power or difference in frequency peak between any of these 
6 contributing trials can lead to highly variable GCSR across the frequency range. When this 
occurs, population means are often required to expose patterns in the data. Without consistent 
GCSR patterns at a participant level, sample mean spectrograms were used to identify GCSR 
patterns. The effect of high inter-trial variability at the individual scale is ameliorated by the 
sample wide averaging. The remaining trends should make clear weaker overall patterns in 
cross task GCSR than could have been identified by individual’s spectrograms. Figure 3.6 




Figure 3.6. Trial-by-trial GCSR spectrograms averaged within non-patient and patient groups and both 
groups together. The patient group shows slightly elevated mean GCSR across the task, and at 
middle and lower frequencies. The non-patient and both groups show GCSR slightly above and 
slightly lower than 0 log(μV2). No obvious trial-dependant patterns are discernible.  
 
The group mean spectrograms show high inter frequency variability and to a lesser extent, 
inter trial variability. In the patient group, almost all trials between 12 and 20, 4 – 8 Hz are 
positive. Inter frequency variability is greater, as negative tiles often disrupt otherwise 
positive trials, such as 8Hz, trial 30 in the non-patient group and 7Hz, trial 24 in the patient 
group. Single trial events also become clearer in group spectrograms, i.e. trials 4 and 17 in the 
non-patient group, and trials 7 and 28 in the patient group. Unfortunately, none of these 
features form systemic patterns across trials in either group.  
Single trial events and general gradation patterns both represent different types of 
dynamics in GCSR across the SST. Aside from the previously established U-shaped dynamic 
















also be worth investigating. This thesis is motivated by investigating GCSR dynamics across 
the SST, and thus its direction will be driven by trial based dynamics, not frequency range 
dynamics.  
3.3.3 - Missing data replacement checks.  
The data replacement method produces conservative estimates of the missing data. Therefore 
it should not alter the overall structure of the dataset. To verify that this is the case, we 
examined our complete dataset (with replacement data) via two hypotheses. It is a 
fundamental expectation of the GCSR literature that the patient group should show greater 
GCSR than the non-patient group. Figure 3.6 visually suggests that the data replacement 
method did not alter this. A between-subjects ANOVA compares the total GCSR of the 
patient sample to the non-patient samples. We used this on both our complete ‘replacement’ 
dataset and the ‘original’ dataset with missing data. The presence of the predicted effect in 
both datasets confirms our observation, and confirms that the data replacement method does 
not substantially alter this feature of the dataset, F(1,134) = 3.981, p = 0.048 and F(1,134) = 
5.248, p = 0.023 respectively.  
Secondly, GCSR has been reported with a significant quadratic trend across the 4 – 12 
Hz frequency range. An orthogonal polynomial contrast is used to identify this trend. We 
again used it on both the replacement and original datasets to confirm that the quadratic 
component of frequency is present in both (Trial Type[lin] x SSD[quad] x Frequency[quad], 
F(1,134) = 5.215, p = 0.024) and (Trial Type[lin] x SSD[quad] x Frequency[quad], F(1,134) = 
5.551, p = 0.020) respectively. The data replacement method has not significantly altered 
either of these key features of the dataset. We cannot preclude the possibility that the data 
replacement method has altered some facet of the data structure, but with both features intact 
we can proceed with some confidence regarding the integrity of replacement dataset.    
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3.4 - Medium SSD inhibition accuracy. 
During our analysis of individual’s GCSR across the task, we noticed that one of the non-
patients failed to inhibit their response on 32 of their 33 medium SSD stop trials. The medium 
SSD condition is the SSD level that is manipulated to impose high goal conflict conditions 
upon participants. To do this the medium SSD is varied instance to instance to promote 50% 
inhibition accuracy – i.e. failing to inhibit their response on 16 or 17 of the 33 medium SSD 
trials. Because this manipulation was so ineffective for this participant we decided to 
investigate the medium SSD inhibition accuracy for all participants.  
Figure 3.7 shows the number of medium SSD trials accurately inhibited for the non-
patient and patient samples. The high conflict manipulation of the medium SSD condition was 
not uniformly effective. It is maximally effective if 16 or 17 medium SSD stop trials are 
accurately inhibited. Most of both samples did not experience the ideal high conflict 




Figure 3.7. Frequency distribution of medium SSD stop trials for non-patient and patient groups. The 
frequency distribution shows that the high conflict manipulation was not effective for all of sample. The 
distributions for both samples peak within the high conflict zone. Both samples show that for many 
participants the conflict manipulation in the medium SSD was not effective. The patient sample shows 
a normal distribution centred around the 16th trial shown in black. It is the basis on which effective and 
ineffective manipulation subgroups are defined, shown by the dashed red lines.   
Without an effective high conflict manipulation the fidelity of GCSR to the underlying 
theory is compromised. Some participants do not experience a contrast in the levels of 
conflict between these conditions. Their GCSR should be lower as a result. Subsequently, 
these ineffective sub-groups of non-patient and patient samples should show lower mean 
GCSR than the effective high conflict manipulation subgroups.  
3.5 - High and low inhibition accuracy subgroups – the manipulation effectiveness 
factor. 
Figure 3.7 shows that the non-patient and patient samples both skew to the left, toward less 
trials successfully inhibited. The patient sample shows a normal distribution of trials inhibited 
between 12 and 21 which is centred on the 50% successful inhibition mark (16 trials 
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successfully inhibited). This is shown by the black distribution in the figure 3.7. The normal 
distribution of error in this sample was used to define effective and ineffective manipulation 
groups. The non-patient sample does not show a clear normal distribution like the patient 
sample. In its absence we used the same cut-off as the patient sample.  
The manipulation effectiveness factor divides each sample into effective and 
ineffective manipulation subgroups. The effective manipulation groups were those non-
patients and patients that successful inhibited 12 or more of their medium SSD stop trials. 
Whereas the ineffective group were those non-patients and patients that successfully inhibited 
11 or less of their medium SSD stop trials. The resulting groups are based on patient status 
and manipulation effectiveness factors. The demographics of the groups are outlined in table 
3.2. 
Table 3.2. Demographic details of the 4 groups defined by the patient status and manipulation 
effectiveness factors.  
Sample Manipulation effectiveness n sex(M/F) Age(mean ± SD) handedness(L/R) 
Non-patient Effective           (NP-EM) 49 16/33 24.3 ± 6.9 0/49 
 Ineffective        (NP-IM) 30 7/23 31.3 ± 9.4 4/26 
Patient Effective                  (P-EM) 38 7/31 32.9 ± 10.8 5/33 
 Ineffective               (P-IM) 19 3/16 35.1 ± 10.3 0/19 
 
A two factor ANOVA (patient status and manipulation effectiveness) was used to investigate 
the difference in mean age between the samples. The ANOVA revealed a main effect of 
patient status (patient status, F(1,136) = 13.326, p = 0.0003) and a main effect of manipulation 
effectiveness (manipulation effectiveness, F(1,136) = 7.392, p = 0.007). Age appears to 
dramatically lower in the NP-EM group alone – the mean is five years less than the next 
lowest group. This might be expected to cause an interaction effect of the two factors, 
however, this was not supported by the ANOVA, (patient status x manipulation effectiveness, 
F(1,136) = 2.034, p > 0.15). 
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3.5.1 - Manipulation effectiveness and GCSR – the manipulation check. 
Manipulation effectiveness is a factor throughout the analyses in this thesis. This is the first 
investigation of manipulation effectiveness within the GCSR literature. Therefore we have 
only theory on which to base a priori hypotheses of manipulation effectiveness’ effect on 
GCSR. Gray’s theory implies that the absence of high conflict manipulation will lead to lower 
GCSR. The defining difference of the manipulation effectiveness factor is fidelity or infidelity 
to the high conflict condition. The comparison between effective and ineffective manipulation 
groups serves as a pseudo-experimental manipulation check. The manipulation effectiveness 
factor can be used to examine whether GCSR responds as predicted to the absence to the high 
conflict manipulation.  
The P-EM group should show the greatest overall GCSR. It is the group in which both 
factors should produce greater GCSR. Counter to this is the NP-IM group. It is expected to 
show the lowest overall GCSR because it is the group with conditions that should decrease 




Figure 3.8. GCSR measured in log(μV2), averaged across the task, across the 4 – 12Hz range for the 
subgroups of two factors; patient status (Non-patient vs. Patient) and manipulation effectiveness 
(effective vs ineffective manipulation). All groups generally show positive GCSR across the frequency 
range. Patients tend to show greater GCSR than non-patient groups and are clearly defined by a 
double peak structure.   
Manipulation effectiveness does not alter the impact of patient status on GCSR - both patient 
groups shows greater GCSR than their non-patient counterparts. The two exceptions to this 
finding occur in the 10 – 12 HZ range of the effective manipulations groups, and at the 7 Hz 
value in the ineffective manipulation groups. In both of these cases patient group mean GCSR 
is decreased relative to the rest of the groups GCSR, while the non-patient groups GCSR 
remains relatively consistent. Whilst this finding is supported statistically (see section 3.3.3), 
it is not the case across the entire frequency range.  
 Our expectation of the effect of the manipulation effectiveness on GCSR was 
inaccurate. The non-patient groups did conform to our expectations; within non-patient 







manipulation group at all frequencies except 9 & 10 Hz. However, the patient groups did not 
conform to our expectations. The patient groups had similar GCSR across the 4 - 6 Hz range 
but contrary to expectations the ineffective manipulation group had greater GCSR than the  
effective manipulation group across the 9 – 12 Hz range.  
 The effect of the manipulation effectiveness factor on GCSR was different from our 
expectations. The data shown in figure 3.8 lead to an alternate a posteri hypothesis, that 
effective manipulation alters the patient factor - GCSR relationship from the ineffective 
manipulation groups. This type of relationship is plausible; Gray’s theory of anxiety would 
suggest that patient GCSR should be greater than non-patient GCSR in effective manipulation 
groups, but not so in ineffective manipulation groups. However, figure 3.8 shows that the 
opposite effect, patient factor GCSR differences are greater in the ineffective group. This 
effect seems most prominent in the upper part of the frequency range i.e. 9 – 12 Hz. To 
support this finding, we tested it with an orthogonal polynomial contrast using three factors, 
patient status, manipulation effectiveness, and trial number. The most prominent pattern 
across trials was quadratic, (patient status [lin] x manipulation effectiveness [lin] x TrialNum 
[quad], F(1,134) = 2.764, p = 0.099). However, this and other results were not significant 
upon correction for multiple comparisons.   
Further hypotheses regarding the impact of manipulation effectiveness in this thesis 
are aligned with the data reported above. Despite contradicting our initial theoretical 
expectation, this new hypothesis is theoretically plausible. Although it is not statistically 
supported this updated hypothesis is superior to the previous one, simply because it is derived 
from data, as opposed to theory.  
3.6 - Trial based analysis – patient status and manipulation effectiveness.  
The effects we observe in the group means provide the starting point for our trial-by-trial 
analysis. This began by identifying features of single trial analysis that differ between the four 
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subgroups in the manner previously outlined (end of section 3.5.1). The two primary features 
we examine are single trial patterns and general gradation patterns. These two patterns are 
chosen because they are easy to define (as per section 3.3.2) and can be tested via orthogonal 
polynomial contrast. Figure 3.9 shows the mean spectrograms for the subgroups of the patient 
status and manipulation effectiveness factors. The subgroup spectrograms should mimic the 
effects seen in figure 3.8.
 
Figure 3.9. Population mean spectrograms for the subgroups of two factors; patient status (Non-
patient vs. Patient) and manipulation effectiveness (effective vs ineffective). The spectrogram shows 
mean GCSR power - log(μV2) ranging between -0.4 log(μV2) – darkest blue, and 0.4 log(μV2) – 
darkest red.  
The patient status increase in GCSR between the effective manipulation groups occurs from 
the 7th trial onward. The first 6 trials of the P-EM spectrogram are similar in magnitude to the 
NP-EM group (note the abundance of light blue tiles and lack of red tiles). A similar effect 
also occurs between the ineffective manipulation groups. After the 11th trial, the P-IM shows 
greater GCSR than the NP-IM group. The first 11 trials in each group are relatively similar, 
both spectrograms show a high portion of orange and yellow tiles and very few dark blue 
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However, in the P-IM group, positive dark red tiles also become more abundant. This does 
not occur in the NP-IM.  
 Single trial events appear in the group spectrograms of figure 3.9. They are present in 
all four groups e.g. trials #7, 12, & 17 in the NP-EM group trials #7, 13, 23, 27, & 28 in the P-
EM group, trials #3, 4, & 20 in the NP-IM group, and trials # 3, 7, 13, 18, & 24 in the P-IM 
group. Despite the presence of single trial event, frequency to frequency variability is still 
high. It can be seen in the presence of lonely tiles, e.g. 7 Hz, trial 22, of the NP-EM group, 10 
Hz trail 2, of the NP-IM group, and 7 Hz, trial 33, of the P-IM group.  
 Due to the difficulty in visually detecting the complex patterns in GCSR across trials 
the first trial-based analysis remained primarily exploratory. Our initial analysis of trial 
dependant patterns took the form of a four-factor orthogonal polynomial contrast; patient 
status, manipulation effectiveness, frequency, and trail number. None of the tests produced 
meaningful results. It is unsurprising given the crude use of this technique to detect 
fluctuation across 33 trials, particularly given the highly variable nature of the inter-trial and 
inter-frequency fluctuation.   
3.7 - Frequency band smoothing. 
High frequency-to-frequency variability arising from the discrete nature of the FFT can be 
ameliorated by smoothing. Smoothing frequency across the 4 – 12 Hz band is common 
practice in previous GCSR publications (Shadli et al, 2015; Shadli et al, 2016). In these 
publications it is used to remove frequency band jitter. Trial based patterns in GCSR should 
become clearer when frequency-to-frequency variability is removed. Figure 3.10 shows the 




Figure 3.10. Subgroup mean spectrograms smoothed across the 4 – 12 Hz frequency range. A. shows 
3-point smoothing of frequency, resulting in a 5 – 11 Hz frequency band. B. shows 3-point frequency 
smoothing of panel A. The resulting 6 – 10 Hz frequency band shows trial, or multi-trial GCSR events. 
GCSR units are as previous figures.    
Figure 3.10 reveals prominent trial based events are prevalent in each of the four groups to 
varying degrees. The P-IM group shows a greater magnitude and number of events across the 
task than the other groups. In the other three groups, trial events are either less defined, less 
regular, or of lesser intense.  
The definition, intensity, and regularity of the trail events differ between groups. Panel 
B of figure 3.10 shows the group mean spectrogram for the P-IM and P-EM groups 3-point 
smoothed twice across frequency. The P-IM groups trial occur more regularly than the P-EM 
groups trials, with each event being separated by 3 and 5 trials respectively. The P-IM group 
trials have a greater intensity than the P-EM group trials. The definition of each groups events 
also differ. The P-EM group events tend to spread across 3 trials whereas the P-IM group 
Non-Patient conflict group Patient conflict group
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trials tend to be isolated to a single trial. The P-IM and P-EM groups are simply an example; 
each pair of groups have unique trial event differences between them.  
A secondary orthogonal polynomial contrast was applied to the smoothed dataset with 
the purpose of exploring complex patterns across the task. Similar to the previous analysis 
this one involved four factors; patient status, manipulation effectiveness, trial number, and a 
smaller frequency range. There were no significant effects arising from this analysis, again 
probably owing to inter trial variance. 
Different types of trial events are each representative of unique cross task dynamics in 
GCSR. As shown in figure 3.10 the differences between groups span multiple dynamics. To 
properly assess the cross task differences between groups, the full range of cross-task 
dynamics should be examined. 
3.8 - GCSR fluctuation – Fast Fourier Transform.  
To examine the full range of cross-task GCSR dynamics we used Fast Fourier 
Transform (FFT). A Fourier transform is used to decompose a complex signal into its 
constituent parts. We used the 33 trials in the SST as consecutive samples of the signal that 
the Fourier transform is applied to. An FFT was applied to each frequency of the individual’s 
original GCSR data (including data replacement). The FFT output shows the magnitude of 
cross-task dynamics. It is measured in (log(µV2))2 across the 0 – 16 cycles per task range. It is 
a unit of the power of fluctuations in GCSR power across the task. From here onward the FFT 
output is referred to as the GCSR fluctuation rate (GCSR-FR). A peak in GCSR-FR appears 
as repetitive increases in GCSR evenly spaced out across the task. Similarly, a trough 
represents an absence of repetitive component. The repetitive increases in power do not 
account for all of a single trials GCSR power. Peaks simply identify a pattern of increase in 




Figure 3.11. The group means of individual’s FFT for each frequency, 4 – 12 Hz resulting in GCSR-FR 
across the fluctuation rate dimension (cycles per task). The group mean FFT is then 3 x 3-point 
smoothed to fit with panel B of figure 3.10 resulting in a range of 6 – 10 Hz. These smoothed 
frequency values are distinguished via colour (grey – black) and thickness (thick – thin). GCSR-FR is 
measured in (log(μV2))2. The 0 cycles per task data point is the component of the FFT output that 
compares the unfluctuating power of each of the five frequency values.     
In figure 3.11 the 5 frequencies generally bunch together (as in 9 – 12 cycles per task, NP-EM 
group) or spread out (as in 2 cycles per task, P-IM group). Bunched together frequencies 
indicate that there was very little difference between the original frequencies in their GCSR-
FR. Spread out GCSR-FR between frequencies indicates diverse rates of cross task 
fluctuation in the unsmoothed 4 – 12 Hz range. When the frequencies spread-out they tend to 
spread in a very orderly fashion, with similar distances between them. This is unsurprising, 
because 3 x 3-pt smoothing across the original range produces highly co-dependent 
frequencies.  

























































Non-Patient conflict group Patient conflict group
Non-Patient non-conflict group Patient non-conflict group
NP – EM group P – EM group



































































































































 A variety of features distinguish GCSR-FR between the four groups. Figure 3.11 
shows the general decay of GCSR-FR across the cycles per task range. Decay across the 
‘frequency’ dimension – cycles per task in this instance, is a common feature of FFT output. 
It is the most prominent in the P-EM and NP-IM groups. It is also present in the P-IM group 
but it is impeded by prominent peaks in at 9, 11, and 16 cycles per task. All four groups show 
peaks and troughs as part of variation across the cycles per task range. The final notable 
feature are the particularly prominent peaks and troughs such as at 9 and 11 cycles per task in 
the P-IM group.   
3.9 - Final/primary analysis 
The primary analysis assesses the hypothesis that manipulation effectiveness will alter the 
patient status effect on GCSR-FR. It is informed by our previous observation of this effect on 
gross GCSR (section 3.5.1). Such a finding may offer an avenue for increasing the sensitivity 
of the biomarker. The pattern of GCSR-FR across the cycles per task dimension is too 
complex to draw visual hypotheses. Due to this, the formal hypothesis does not speculate on 
nature of the pattern within GCSR-FR. It is simply that a GCSR-FR component difference 
depending on patient status will be mediated by manipulation effectiveness. To this end, the 
investigation of intra task effects is exploratory. There is no justifiable prediction of what 
component of GCSR-FR is affected by the two factors. The hypothesis remains simply that an 
effect is present.   
 Two secondary hypotheses are also assessed in this analysis. These are the main 
effects of each of the two factors. The hypotheses only pertain to total GCSR-FR, and as such 
are secondary to the aim of investigating the nuances of intra-task fluctuation. They are that 
there will be a gross effect of patient status and of manipulation effectiveness on GCSR-FR. 
These are informed by our theoretical expectations of each factor; that effective manipulation 
is associated with greater GCSR than ineffective manipulation, and secondly that patient 
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status is associated with greater GCSR than non-patient status. Section 3.3.3 does provide an 
empirical basis for the main effect of patient status, showing that there is such an effect on 
gross GCSR.  
 
3.9.1 - Banding and compression of GCSR fluctuation. 
To simplify this analysis the frequency range was split into three bands. The 4 – 12 Hz range 
was split into a 4 – 6 Hz ‘theta’ average, a 7 – 9 Hz ‘low alpha’ average, and a 10 – 12 Hz 
‘high alpha’ average. Banding the frequency range is useful for several reasons. Similarly to 3 
point smoothing, banding reduces the effect of inter-frequency variability. Banding also 
simplifies the visual interpretation of GCSR-FR. Banding also ensure the frequency bands are 
mathematically independent of each other Because banding achieves this it is the preferred 
method of simplifying the frequency range as opposed to smoothing which produces highly 
co-dependent frequencies. GCSR-FR banded across the frequency range is shown in panel A 
of figure 3.12.    
In the final analysis GCSR-FR is compressed by trial-based pair wise averaging. Panel 
A of figure 3.12 shows GCSR-FR at its original resolution and the variability from value to 
value. Panel B of figure 3.12 shows the compressed, banded GCSR fluctuation for all four 




Figure 3.12. Group means of individuals FFT of GCSR across the SST. GCSR is split into three bands 
across the 4 – 12 Hz frequency range into 4 – 6 Hz (light grey), 7 – 9 Hz (dark grey), and 10 – 12 Hz 
(black) bands. A. FFT results at original resolution, 1 – 16 cycles per task. B. FFT results compressed 
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3.9.2 - Patient status and manipulations effectiveness’ effect on banded GCSR fluctuation. 
The primary hypothesis outlined in section 3.9 was supported. One of the two secondary 
hypotheses were supported.Interestingly, patient status does not affect GCSR-FR 
whereas.manipulation effectiveness does.  
 Effective manipulation increases GCSR-FR relative to ineffective manipulation. This 
was supported by factor ANOVA (patient status x manipulation effectiveness x band [int]) 
which found a significant effect of manipulation effectiveness, (F(1,134) = 4.028, p = 0.047). 
Patienthood did not increase GCSR-FR as predicted. The main effect of patient status in the 
same ANOVA was not significant. Figure 3.13 shows the contrast of GCSR-FR based on 
manipulation effectiveness. Post-hoc band specific ANOVA’s reveal that this effect is derived 
from the low alpha and high alpha bands, (F(1,134) = 4.006, p = 0.047) and (F(1,134) = 
4.178, p = 0.043) respectively. 
 
Figure 3.13. The contrast of effective and ineffective manipulation on GCSR-FR. Ineffective 
manipulation GCSR fluctuation is subtracted from effective manipulation GCSR-FR to give the conflict 
specific GCSR-FR. GCSR-FR magnitude is measured in (log(μV2)2) 
 
Manipulation effectiveness changes the patient factor relationship with GCSR-FR. Patient 
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different directions. It has a quartic trend (m or w shape, depending on band) across GCSR-
FR.  
The primary analysis revealed that theta, low alpha, and high alpha bands show a 
linear progression in the quartic pattern across GCSR-FR. This was verified by orthogonal 
polynomial contrast, (patient status [lin] x manipulation effectiveness [lin] x band [lin] x 
cycles/task [quartic], F(1,134) = 12.504, p = 0.0006). To correct for multiple comparisons, the 
p value is multiplied by the number of alternate checks. The resulting correction demonstrates 
the strength of the effect; F(1,134) = 12.504, p =0.007. Band specific post-hoc analyses shows 
that this effect was derived from reciprocal quartic patterns in the theta and high alpha bands; 
theta – (patient status [lin] x manipulation effectiveness [lin] x cycles/task [quartic], F(1,134) 
= 6.294, p = 0.013), high alpha – (patient status [lin] x manipulation effectiveness [lin] x band 
[lin] x band [lin] x cycles/task [quartic], F(1,134) = 5.875, p = 0.017). Figure 3.14 shows the 
difference in the patient factor – GCSR-FR relationship between effective and ineffective 
manipulation. Positive values mean that the difference between mean patient GCSR-FR and 
mean non-patient GCSR-FR is greater in effective manipulation conditions. Negative values 
mean that the difference between mean patient GCSR-FR and mean non-patient GCSR-FR is 




Figure 3.14. The difference in patient factor – GCSR-FR between manipulation effectiveness 
conditions, for the theta, low alpha, and high alpha bands. The theta and high alpha bands show 
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Chapter 4: Discussion 
4.1 - Aims, analyses & results of study. 
The aim of this thesis was to investigate the dynamics of GCSR across the SST, and whether 
intra task dynamics could contribute to improved patient status predictability. An alternate 
summary of GCSR - GCSR-FR measures those intra task dynamics. It could be superior to 
the traditional summary of GCSR. This investigation showed that there are differences in 
GCSR dynamics associated with . Critically it also illuminated GCSR-FR patient group 
differences that are associated with underlying theory of anxiety. This finding satisfies two 
key points; refining patient status predictability through group mean differences and 
adherence to  Gray’s theory of anxiety, which indicate these trial based dynamics could be 
used to refine patient status prediction. The investigation was comprised of three steps. 
4.1.1 - Preliminary analyses. 
The first step verified that our method of replacing missing data did not compromise the 
overall structure of the data. We replicated two features of the raw GCSR dataset in the 
complete replacement set to demonstrate that the alterations had minimal impact on the 
structure of the dataset. These analyses included significant quadratic trend across the 4 – 12 
Hz frequency range and a significant effect of patient status. A complete dataset is necessary 
for the development of GCSR-FR, the measure that the primary analysis is based on.  
The second step attempted to verify the observation of the combined effect of patient 
status and manipulation effectiveness on GCSR. We observed that non-patients average 
GCSR (across the 4 – 12 Hz range) decreased without effective manipulation whereas average 
GCSR increased without effective manipulation within patients.  An analysis was conducted 
in the form of an ANOVA to verify this observation. It was not supported. 
The observational hypothesis of manipulation effectiveness altering the patient factor 
– GCSR-FR relationship was derived from impact of these factors on total GCSR. The initial 
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hypothesis of the effect of manipulation effectiveness on GCSR-FR was based on theoretical 
expectation of manipulation effectiveness on total GCSR. Despite neither of these hypotheses 
being supported at the total GCSR level, they were maintained into the final step, the primary 
analysis. The main hypothesis of this analysis addressed was the exploratory hypothesis that 
some GCSR-FR component difference would occur in the patient status factor, depending on 
the manipulation effectiveness condition. The GCSR-FR dynamic was the primary interest, 
but group effects of the two factors were also assessed.  
4.1.2 - Primary analysis.  
This is the first investigation of GCSR dynamics across the SST. It showed that GCSR is not 
uniform across the task. GCSR-FR is an alternate summary of GCSR that explicitly accounts 
for intra task variation in GCSR. The primary analysis shows that the patient factor – GCSR-
FR relationship is effected by manipulation effectiveness. It highlights potential targets for 
improving patient status prediction. Figure 3.14 in section 3.9.2 shows that the relationship of 
the differences in patient factor - GCSR-FR relationship between manipulation effectiveness 
groups is quartic for the theta (4 – 6 Hz) and high alpha (10 – 12 Hz) bands. 
Reliable differences between the patient and non-patient groups can be used to refine 
patient status predictability at an individual level. GCSR-FR provides an alternate dimension 
to the anxiety process biomarker because it accounts for intra task GCSR dynamics. GCSR-
FR accounts for the parts of the fluctuation dimension that would otherwise be detrimental to 
patient status prediction. Because of this, it is superior to traditional summaries of GCSR that 
simply lump them all together.  
Further research is required to develop and test a hypothesis of why the trend is 
quartic. The quartic pattern may arise because the participants of a group may preferentially 
employ a unique trial strategy (or other factor contributing to GCSR i.e. attention or arousal) 
relative to the other three groups. Each of these trial strategies may possess unique cross-task 
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attention spans and refractory periods such that, on aggregate, they occur periodically 
throughout the SST.  
These single group differences could then appear as GCSR-FR differences that lead to 
differences in the patient factor – GCSR-FR relationship between manipulation effectiveness 
conditions. Due to the reciprocal nature of theta and high alpha bands, unique GCSR-FR 
peaks occurring this way appear to compensate for increased single group difference in 
periodic theta power with lower periodic high alpha power, or vice versa.  This explanation is 
speculative and testing any hypothesis is difficult.    
 The quartic trend across GCSR-FR suggests that there may be five different trial 
strategies. Each of the five strategies correspond to one of the peaks or troughs of the quartic 
trend in figure 3.14. In this case, strategies that peak frequently such as at 7.5 cycles per task, 
could interfere with strategies with that peak less frequently, such as at 1.5 cycles per task, in 
a harmonic manner. Interference like this could occur in both constructive or destructive 
manner, leading to greater or lesser overall GCSR-FR respectively. This type of interference 
could mean that there are less than five strategies, with the less frequent GCSR-FR peaks 
occurring incidentally as a result of the more frequent GCSR-FR peaks.  
An alternate hypothesis is that the peaks troughs in GCSR-FR are the result of ultra-
slow rhythmicity (Rodin, 2015; Rodin et al, 2017). Rodin et al, (2017) warns that ultra-slow 
waves (< 0.5 Hz) exist in human EEG. They specifically identify wave durations ranging 
from 10 – 35 minutes occurring in medial inferior frontal area’s, whereas GCSR is measured 
at the, lateral, rIFG. Each requires 3000ms (see figure 2.1) and each ‘GCSR trial’ takes up 12 
the duration of 12 trials, thus a ‘GCSR trial’ takes 36 seconds. The most frequent cycles per 
task peak occurs at 15.5 cycles per task. For comparison, 16 cycles per task equates to an 
oscillation every 72 seconds, which is equivalent to 0.0138 Hz wave. These fall within the 
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range of identified by Rodin et al. These may aggregate to be greater in a specific group 
because of changes in motor control or attention (Rodin et al, 2017). 
The primary analyses also showed that effective manipulation is associated with 
greater net GCSR-FR when the bands (theta, low alpha, and high alpha) are summed together 
(section 3.9.2). Figure 3.13 shows that this effect is largely consistent across the GCSR-FR 
range, except for at 3.5 cycles per task. Unfortunately, the patient status factor does not 
significantly affect GCSR-FR as hypothesized. The relationship between them is appears to 
be more complex, as seen in figure 3.14. Patient status predictability is a key requirement for 
the clinical progression of the biomarker. Therefore, the positive finding of manipulation 
effectiveness is less useful because it does not directly contribute toward patient status 
discrimination. 
4.2 - Assessing the progression of GCSR toward clinical use. 
There are two ways to assess the clinical progression of a biomarker. They can be assessed as 
a biomarker of DSM-V anxiety disorders or as aligned with the aim of the RDoC. The aim of 
the RDoC is to classify mental disorders objectively, in doing so aligning the 
classification/diagnosis of a disorder with its biological cause. GCSR is based on Gray’s 
theory of anxiety and fulfils the requirements of the RDoC by objectively defining the 
disorder it measures (section 1.5.6). To progress the biomarker toward clinical use in this 
manner any improvement in patient status prediction must adhere to underlying theory. 
Counter to this, in assessing clinical progression as a biomarker of DSM-V anxiety, an 
improvement in patient status prediction does not need to adhere to the underlying theory. 
Improving patient status prediction is important for either assessment, but adherence to 
Gray’s theory of anxiety is critical to progressing GCSR toward the objective classification 
and diagnosis of an anxiety disorder.  
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The manipulation effectiveness factor contrasts Gray’s ‘anxiety’ induction between 
the GCSR measured in either condition. Participants in the ineffective manipulation condition 
did not experience the high conflict manipulation. These participants’ medium SSD inhibition 
accuracy indicates a low goal conflict induction, similar to that of the short and long SSD. 
Without the contrast of high and low conflict conditions GCSR is not a measure of goal 
conflict. The manipulation effectiveness factor is pseudo-experimental, a point that is 
elaborated on in the limitations section. Thus the ineffective manipulation condition is an 
imperfect control group to the effective manipulation conditions. The distinction of the factor, 
and the subsequent hypotheses are a-posteri which limits the theoretical rigour of the 
distinction – as is widely the case in exploratory work. 
The primary analysis of this thesis shows that some GCSR-FR values show a greater 
difference between patient and non-patient in effective manipulation conditions than the 
ineffective manipulation condition. Mathematically there are two causes of this effect. A 
negative difference between P-IM and NP-IM groups that is absent between P-EM and NP-
EM groups. Conversely, a positive difference between P-EM and NP-EM groups that is 
absent between P-IM and NP-IM groups will also produce this effect. Because the 
manipulation effectiveness factor contrasts association with Gray’s theory of anxiety, the 
second of positive effect causes is particularly relevant to RDoC style progression of the 
biomarker.   
4.3 - Clinical progression based on GCSR fluctuation rate. 
To improve patient status prediction with GCSR-FR the manipulation status of the participant 
is required. Both of the primary findings of this thesis involve the distinction of manipulation 
effectiveness, however only the latter of these can improve patient status prediction. GCSR-
FR values that are positive in figure 3.14 show greater patient factor differences for those in 
the effective manipulation condition, whereas negative values show greater patient status 
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prediction for those in the ineffective manipulation condition. Binary logistic regression can 
predict the patient status of the individual based on the GCSR fluctuation of the individual. 
One of the causes of positive differences in figure 3.14 is when the P-EM and NP-EM 
groups that are not present between the P-IM and NP-IM groups. GCSR fluctuation 
differences of this type is associated with Gray’s theory. These group differences potentially 
allow for improved patient status prediction that is consistent with theoretical base of the 
biomarker. Clinical progression in this manner is required to achieve the goal of the RDoC. 
GCSR fluctuation could progress the biomarker without compromising the adherence to 
Gray’s theory. The cause of group differences need to be identified to enable progress this 
way, which may require the deconstruction of the GCSR fluctuation dimension.   
The theoretical consistency of the anxiety specific patient group differences outlined 
above is limited because it is based on the manipulation effectiveness factor. GCSR measures 
anxiety by mimicking the behavioural conditions that correlate with RSA. Thus, the 
theoretical link the manipulation effectiveness factor provides for the GCSR-FR finding is 
also behavioural. Compared to the objectivity that is desirable in a mental disorder biomarker, 
mimicking behavioural conditions is a tenuous link to the underlying theory.  
4.4 - Future research – clinical progression of the biomarker.  
Future research building on this thesis should focus on improving patient status prediction 
with GCSR-FR. The first point of follow up research is a replication of the current result. The 
findings in this thesis are complex, and may arise purely by chance. Replication protects 
against statistical anomaly. It is also a critical part of the scientific process which is often 
overlooked.  
The second point is to derive and test a hypothesis to explain the primary result. This 
thesis demonstrates that the patient factor – GCSR-FR relationship differs between 
manipulation effectiveness conditions in a quartic manner across the GCSR-FR. The 
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complexity of this finding complicates the process of deriving a hypothesis to explain it. We 
tentatively suggest two potential explanations for the primary effect in the previous section.      
The third point of future research is pharmacologic verification. It is the only way to 
objectively show anxiety exclusive differences in GCSR-FR patient group differences. The 
type of group differences outlined above suggest that specific GCSR-FR is associated with 
Gray’s theory of anxiety.. Gray’s theory of anxiety is based on the reduction of RSA by 
anxiolytic drugs. The behavioural conditions that suggest these GCSR-FR values are 
associated with the patient group and therein greater anxiety. However well supported Gray’s 
theory of the behavioural effect of these drugs, it is subjective support. Anxiolytic suppression 
of the GCSR-FR – patient status link would provide unparalleled objectivity.   
4.5 - Limitations 
This are several limitations to this study, which limit the strength of the conclusion it draws. 
The first limitation of this thesis is the influence of replacement data on GCSR-FR. The 
method used in this thesis is a trial-based approach. It uses least-squared error interpolation to 
replace missing data. An FFT requires a complete dataset to produce output. Therefore, 
replacement data is necessary. GCSR-FR may differ from what the output would be if the 
organic dataset were complete. The current method of data replacement is suitable for 
calculating GCSR-FR. The least-squared-error method minimises inorganic GCSR-FR 
because of data replacement. However, some organic GCSR-FR may be absent due to 
missing trials. The least-squared error method does not address the absent GCSR-FR.  
 An alternate method of replacing missing data may be superior to the trial-based 
approach. Missing trial data occurs because the original EEG recording is missing samples. 
Sometimes the EEG recording may be missing the entire trial’s samples. Other times it may 
be that only one sample is missing. The FFT used to extract frequency power values for 
individual trials needs a complete EEG recording. Therefore, even one missing sample can 
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cause missing trial data. Replacing missing samples in the original EEG can address missing 
trial data. Where applicable it is a better method of data replacement than the trial-based 
method developed in this thesis. Using these two methods in conjunction is the best option. 
The trial based method should be used to fill in missing trial data when the entire trials EEG 
recording is missing. The EEG based method of data replacement should used at all 
opportunities. 
The second limitation is the weakness of the manipulation effectiveness factor. 
Manipulation effectiveness as measured in this thesis is based on the accuracy of medium 
SSD stop trial inhibition. The medium SSD is the high conflict condition in the SST. It 
implies accurate inhibition on 50% of trials. The high conflict medium SSD is contrasted 
against the short and long SSD’s, which are the low conflict conditions. They are assessed as 
accurate inhibition on 80% and 20% of such trials respectively. To properly assess 
manipulation effectiveness the inhibition accuracy of all three SSD’s should be considered. 
Examining medium SSD inhibition accuracy only assumes that the short and long SSD 
inhibition accuracy conform to design. The assumption of medium SSD inhibition accuracy 
was not been particularly accurate and therefore the short and long SSD’s should also have 
been investigated.   
 Manipulation effectiveness is a pseudo experimental factor. Because of this, the 
presence of an underlying third variable cannot be discounted. Such a variable could be 
responsible for both the differences in medium SSD inhibition accuracy that determine the 
manipulation effectiveness groups and its effect on task fluctuation. A third variable may also 
provide an alternate explanation to why total GCSR does not conform to our initial 
manipulation effectiveness – GCSR hypothesis. The analyses in this thesis do not account for 
the difference in mean age across both the patient status and manipulation effectiveness 
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factors. Both factors demonstrate very significant differences in age, making it a potential 
candidate for a third variable underlying the manipulation effectiveness factor.  
 The third limitation is that the patient status groups are dictated by the symptomatic 
definition of anxiety of the current classification system. This leads to a mismatch between 
the group of anxious patients that are defined by Gray’s theory and the patient group defined 
by the current DSM classification. It is expected that the majority of the anxious group 
defined by Gray’s theory will fall within the patient group, primarily because the DSM patient 
group likely encompasses multiple disorder types. In this thesis, patient – non-patient group 
differences are the mark of clinical progression. Because the DSM patient group likely 
encompasses Gray’s anxiety patient group it is still a valid measure of clinical progress. Using 
DSM patient groups as a proxy for Gray’s anxiety patient group is less than ideal. However, 
without an alternate way of identifying Gray’s anxiety patients it will continue to be used.   
The MINI diagnosis demographics (table 2.2) indicate that the patient group are not 
purely anxiety patients. Phobic and depressive disorders are also prevalent within our patient 
group. Gray and McNaughton, (2000) stress the biological difference in function between 
anxiety and fear/panic (for summary see McNaughton & Corr, 2004). This distinction is 
critical to ethological aspect of Gray’s ‘goal conflict’ definition of anxiety. Both of these 
issues contribute to the heterogeneity of the patient group. The heterogeneity of the patient 
group may increase mismatch to the group of Gray’s anxiety patients. This mismatch weakens 
our ability to detect the effects based on patient status and also the theoretical support for the 
conclusions we do draw.   
This study does not contrast the primary finding against a relaxation EEG dataset. The 
primary finding is complex, and the possibility of this effect occurring in any motor inhibition 
(or motor task in general) should not be ignored. The ideal solution is to test relaxation EEG 
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from the same sample for the effect; arbitrarily assign samples from relaxation EEG spaced 
apart as the trials that contribute to GCSR are.   
In this thesis we assert that a novel method of GCSR analysis could be beneficial to its 
clinical progression. To justify this, we imply that our methods of analysis may drive clinical 
progression of GCSR further than traditional methods. We base this on a complex finding of 
group differences in GCSR fluctuation. The complexity of it hinders progression based on our 
method of analysis. It weakens our case that examining intra-task fluctuation provides 
superior analysis compared to averaging across blocks or task. 
 The complexity of our finding is primarily due to the several types of combined 
patient status and manipulation effectiveness effects on GCSR-FR. Within each band’s effects 
neither positive nor negative individual effects are due to the same cause. This complicates 
hypothesis generation about the cause of the group difference of the quartic trend component 
of GCSR fluctuation. The difficulty of further research building on this finding does limit the 
cogency of the argument.  
4.6 - Theta (4 – 6 Hz) and high alpha (9 – 12 Hz) band reciprocity. 
There is a strong linear progression of the quartic trend across the three frequency bands. In 
figure 3.14 the theta band (4 – 6 Hz) shows a negative quartic shape across GCSR fluctuation, 
whereas the high alpha band (10 – 12 Hz) shows a positive quartic shape. The reciprocity of 
theta band and alpha band rhythmicity is a common feature of EEG recordings across the 
cortex (Klimesch, 1999).  
We suggest that the primary finding in this thesis may occur as unique trial strategies 
manifesting as cross task dynamics in GCSR. The distinction of trial strategies, and therefore 
the explanation of this result is primarily cognitive. Future research may define individual 
trial strategies behaviourally. Therefore, the reciprocal effects of theta and high alpha bands 
may be driven by this phenomenon outlined above.  
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As stated earlier (section 4.1.2), the peaks and troughs in figure 3.14 may occur 
because unique trial strategies are being preferentially employed by a single group. Each of 
these strategies could be underpinned by alpha or theta band rhythmicity. For example, when 
an alpha dominant strategy is employed, alpha power would increase and correspondingly, 
theta power would decrease. As the use of this trial strategy fluctuates across the task, high 
alpha band GCSR-FR would increase in a positive direction, and correspondingly, theta band 
GCSR-FR would increase in a negative direction. Three alpha dominant trial strategies appear 
to manifest at 1.5 and 7.5 cycles per task values, and to a lesser extent at between 13.5, and 
15.5 cycles per task. Vice versa, the fluctuation of theta dominant strategies across the task 
leads to a positive increase in theta band GCSR-FR, and a negative increase in high alpha 
band GCSR-FR. The GCSR-FR in figure 3.14 indicates the presence of two theta dominant 
trial strategies. They appear to manifest between 3.5 and 5.5 cycles per task as-well as 
between 11.5 and 13.5 cycles per task.   
4.7 - Manipulation effectiveness.  
This thesis is the first investigation of the effectiveness of the conflict manipulation in the 
SST. It is a basic form of manipulation check for GCSR. Previous GCSR publications have 
not performed checked the high conflict manipulation. The results they report include an 
unknown portion of ineffective conflict manipulation participants. Figure 3.8 (section 3.5.1) 
shows plots of the total GCSR across the task for all four subgroups. Comparing the total 
GCSR of the NP-IM group to the NP-EM group suggests that the inclusion of ineffective 
manipulation participants in previous reports of GCSR may decrease total GCSR across 
most of the frequency range, excepting at 9 & 10 Hz respectively. The extent of this issue in 
broader GCSR literature, and thus the misrepresentation of true GCSR is unknown.  
The most basic test of the GCSR biomarker with manipulation effectiveness is that 
P-EM power is greater than NP-EM. The conflict manipulation is critical to Gray’s theory of 
68 
 
anxiety that GCSR is based. When the manipulation is effective the patient GCSR should be 
greater than non-patient GCSR. Figure 3.8 (section 3.5.1) shows that within non-patients the 
effective manipulation group showed greater GCSR than the ineffective group.  
The natural extension of our initial theoretical prediction for the manipulation 
effectiveness factor was to predict the same effect irrespective of patient status. However, 
our data shows that manipulation effectiveness does not affect GCSR this way. Instead we 
observed the inverse, that the non-effective manipulation group showed greater GCSR. A 
posteri hypothesis derivation is not desirable scientific practice. In this instance it was 
necessary – it is the first report of this distinction, and thus there is no prior data to inform 
our hypotheses. The a priori theoretically informed hypothesis was contradicted by the data. 
Despite the difference not being supported statistically this hypothesis was extended into the 
final analysis. 
The final analysis shows that manipulation effectiveness also effects patients status’ 
relationship with task rhythmicity. Our expectations of this effect were informed by the 
findings of aggregate GCSR. Post hoc analysis suggested that the alpha bands were 
primarily responsible for this.  
4.8 – Conclusion 
Mental health disorders need better classification and diagnostic tools (Insel et al, 2010). 
GCSR is a biomarker of anxiety that is based on an empirical definition of anxiety. Thus, it’s 
objectivity far exceeds any current mental health disorder definition. To be clinically useful, 
GCSR needs to predict patient status at an individual level. In its current state it is not.   
 Shadli et al, (2015) demonstrates that GCSR is not consistent across the task. They 
found significant GCSR in block’s 1 and 3, but not block 2. This represents the only previous 
identification of cross task GCSR fluctuation. It was plausible that other cross task GCSR 
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dynamics were hidden within the task. This thesis had two aims; to identify cross task GCSR 
dynamics, and to investigate whether they could be used to improve patient status prediction.  
 To enable cross task GCSR dynamics missing data needed to be replaced. A least 
squared error linear interpolation method of data replacement was developed. It does not 
appear to alter the gross structure of the dataset. Some degree of alteration is inevitable, as the 
data replacement method provides a conservative estimate. A secondary, manipulation 
effectiveness factor was also identified. It distinguishes a pseudo experimental contrast of 
association with the underling theory of anxiety, based on a task performance metric. 
 An FFT was used to measure the full range of intra task GCSR dynamics. It produced 
a novel summary of GCSR: GCSR-FR. The primary analysis revealed that a complex 
component of GCSR-FR is affected  are present in the dataset. This fulfils the first aim of the 
thesis. The primary analysis illustrated the difference in the patient factor – GCSR-FR 
relationship between manipulation effectiveness conditions.  
The primary finding highlights specific GCSR-FR values that show greater GCSR-FR 
in patient groups than non-patient groups, that are present only when in effective 
manipulation conditions. Because the manipulation effectiveness factor is associated with  the 
theory, these GCSR-FR values are of particular interest. They provide an avenue that may, 
with further research help to patient status prediction that is associated with the underlying 
theory of anxiety. Future research based on this finding should centre on the use of GCSR-FR 
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Appendix A. – Information form for non-patients. 
 
 
Stop Signal EEG and Personality 
 
(Principal Investigator: Professor Neil McNaughton, Department of Psychology, 03-479 
7634) 
 
INFORMATION SHEET FOR PARTICIPANTS 
 
Introduction 
Thank you for showing an interest in this project.  Please read this information sheet 
carefully. Take time to consider and, if you wish, talk with relatives or friends, before 
deciding whether or not to participate. If you decide to participate we thank you.  If you 
decide not to take part there will be no disadvantage to you and we thank you for considering 
our request. 
   
What is the aim of this research project? 
This project investigates how the electrical activity of your brain varies when you are trying 
to stop a response once you have started making one. We are particularly interested in how 
one specific brain rhythm (which appears when stopping and going are in conflict with each 
other) relates to current questionnaires that measure anxiety-related traits. The results should 
show how the various personality trait measures relate to trait variation in the conflict 
response and should also provide a basis for developing a new conflict response scale, 
extreme responses on which could potentially be used to diagnose a specific kind of anxiety 
disorder. The brain rhythm data will also provide a reference population against which 
clinical groups can be compared in future. 
 
Who is funding this project?  
This project is part of the work funded by a grant to Professor Neil McNaughton and 
collaborators at the University of Otago and the University of Auckland from the Health 




Who are we seeking to participate in this project? 
We are seeking participants who are 18-40 years old, healthy (with no major illness in the 
previous 30 days), with no regular use of psychotropic medication in the last 6 months and no 
use of alcohol in the 24 hours before testing. You should be willing to receive medical and 
psychiatric screening interviews and undergo a urine test for psychotropic compounds. 
 
You will NOT be able to participate in the project because it may involve an unacceptable 
risk to you if have: 
1. Susceptibility to photosensitivity. 
2. A history of seizure. 
3. A history of allergic skin reactions to chemical agents including detergents. 
 
If you participate, what will you be asked to do? 
For the main part of the test, we will record the electrical activity from your scalp, heart and a 
finger during a ten minute rest period and in a “stop signal” task with stimuli delivered on a 
computer screen and through earphones and to which you will make responses using a 
computer mouse. You will be interviewed about your physical and mental health and also be 
asked to complete several questionnaires that measure aspects of your mood and personality. 
The whole experiment will take about three hours. In recognition of the time, inconvenience, 
and travel costs in attending for testing, you will be compensated at a rate of $15 for each 
hour of attendance.  
 
Preparation for the experiment 
Hair products and natural oils on our scalp make it difficult to record your brain activities. It 
is important to us that you come with a clean scalp. Please avoid using any hair products on 
the day of the experiment.  We recommend that you wash your hair on the day or the day 
before and avoid using a hair conditioner. For participants with glasses, we also recommend 
that you wear contact lenses if possible for your own comfort.  
 
Electrical recording procedure 
You will put on an electro-cap as shown in the picture. We will fill the 
electrodes (small metal discs) attached to the cap with a gel that conducts 
brain signals from your scalp to our recording system. To achieve good 
recordings, we will abrade your skin gently before applying the gel. The 
electrodes are then connected to an amplifier that allows us to record your 
brain rhythms (EEG). We will also attach stick-on electrodes to your 
body to record your heart activity (ECG) and a clip on electrode to an 
index finger to measures your skin resistance/perspiration (GSR). The whole system is 





Is there any risk of discomfort or harm from participation? 
There is a risk of allergic skin reaction to the electrode gel and of minor discomfort from the 
abrasion of the skin surface during gel application. Exposure to stimuli on a computer screen 
has a rare risk of inducing seizures in those with or without a history of seizure. If you have a 
history either of photosensitivity or of any form of seizure you should not take part. The 
person running your electrical testing is required to be trained in the procedures for 
connecting you to the equipment and to have a current First Aid Certificate (with training 
renewed every two years by the New Zealand Red Cross) so that they can respond 
appropriately to any unexpected adverse events that occur during testing. 
 
What data will be collected, and how will they be used? 
Your physical and mental health status, questionnaire scores, and elecgtrical recordings will 
be stored in secure computer databases and will be identified only with your participant 
number. Any paper records will be stored securely in locked filing cabinets. Health status will 
be assessed only to exclude participants who do not meant the entry criteria. Questionnaire 
and electrical data will be subjected to group statistical analysis to determine general group-
wide personality trait relationships and reference data. Urine samples, identified only by 
participant number, will be disposed of by the analysing laboratory using their usual 
procedures and only the qualitative, present/absent, result returned by the laboratory will be 
used for inclusion/exclusion. Data will be stored for 10 years and then deleted. 
 
What about anonymity and confidentiality? 
No identifying data will be recorded. All collected data will be linked only to your participant 
number. All data will be stored securely and accessed only by study personnel. Reporting of 
the completed research will be of aggregated data over all participants and no data will be 
reported linked to an individual participant number. 
 
Can Participants Change their Mind and Withdraw from the Project? 
You may withdraw from participation in the project at any time and without any disadvantage 
to yourself of any kind. 
What if Participants have any Questions? 
If you have any questions about our project, either now or in the future, please feel free to 
contact either:- 
 
Shabah Shadli (Telephone: 03 479 5835) or Professor Neil McNaughton (Telephone: 03 479 
7634) shabah.shadli@otago.ac.nz   nmcn@psy.otago.ac.nz 
 
This project has been reviewed and approved by the University of Otago Human Ethics 
Committee (Health: H 15/005). If you have any concerns about the ethical conduct of the 
research you may contact the Committee through the Human Ethics Committee Administrator 
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(ph 03 479-8256 or email gary.witte@otago.ac.n). Any issues you raise will be treated in 





Stop Signal EEG and Personality 
(Principal Investigator: Professor Neil McNaughton, Department of Psychology, 03-479 
7634) 
CONSENT FORM FOR PARTICIPANTS 
1. I have read the Information Sheet concerning this study and understand the aims of this 
research project. 
2. I have had sufficient time to talk with other people of my choice about participating in 
the study.   
3. I confirm that I meet the criteria for participation which are explained in the Information 
Sheet. 
4. All my questions about the project have been answered to my satisfaction, and I 
understand that I am free to request further information at any stage.  
5. I know that my participation in the project is entirely voluntary, and that I am free to 
withdraw from the project at any time without disadvantage. 
6. I am aware that undergraduate students will be present and will carry out some parts of 
the experiment. 
7. I know that as a participant I will undergo electrical (EEG/ECG/GSR) testing, physical 
and mental health screening, and a qualitative urine test for psychotropic drugs and 
complete questionnaires assessing emotion, as listed in the information sheet. I 
understand that I may decline to answer any interview or questionnaire question without 
disadvantage of any kind. 
8. I know that no personal identifying information will be included in the paper records 
and electronic files which represent the data from the project, and that these will be 
placed in secure storage and kept for at least ten years.  
9. I understand the nature and size of the risks of discomfort or harm that are explained 
in the Information Sheet, including the rare risk of computer screen-induced seizures. 
10. I understand that the results of the project may be published but my anonymity will be 
preserved and only group data reported. 
I agree to take part in this project. 
………………………………………………… 
   (Full name) 
.............................................................................    ............................... 
       (Signature of participant)       (Date) 
This project has been reviewed and approved by the University of Otago Human Ethics 
Committee (Health: H 15/005). If you have any concerns about the ethical conduct of the 
research you may contact the Committee through the Human Ethics Committee Administrator 
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(ph 03 479-8256 or email gary.witte@otago.ac.n). Any issues you raise will be treated in 
confidence and investigated and you will be informed of the outcome. 
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Appendix B. – Information form for patients 
 
 
EEG Testing for an Anxiety Process 
(Principal Investigator: Professor Neil McNaughton, Department of Psychology, 03-479 7634) 
 
INFORMATION SHEET FOR PATIENTS 
 
Introduction 
Thank you for showing an interest in this project.  Please read this information sheet carefully. Take time to 
consider and, if you wish, talk with relatives, friends, or your doctor, before deciding whether or not to 
participate. If you decide to participate we thank you.  If you decide not to take part there will be no 
disadvantage to you and we thank you for considering our request. 
   
What is the aim of this research project? 
This project investigates how the electrical activity of your brain varies when you are trying to stop a response 
once you have started making one. We are particularly interested in how one specific brain rhythm (which 
appears when stopping and going are in conflict with each other) relates to current questionnaires that 
measure anxiety-related traits. The results should show how the various personality trait measures relate to 
trait variation in the conflict response and should also provide a basis for developing a new conflict response 
scale, extreme responses on which could potentially be used to diagnose a specific kind of anxiety disorder. 
We predict that some people with any of a range of anxiety symptoms will have a stronger conflict brain 
rhythm compared both to other people with much the same anxiety symptoms and to a non-clinical 
population. We expect this stronger rhythm will be linked to a greater treatment response. It is important for 
us that we measure this rhythm before you receive any treatment as we already know that a variety of anti-
anxiety drugs strongly affect it. 
 
Who is funding this project?  
This project is part of the work funded by a grant to Professor Neil McNaughton and collaborators at the 
University of Otago and the University of Auckland from the Health Research Council of New Zealand. 
 
Who are we seeking to participate in this project? 
We are seeking participants who are 18-40 years old, who are suffering from ongoing symptoms of anxiety, 
fear, or panic and who are intending to seek treatment for this. You should otherwise be healthy (with no 
major illness in the previous 30 days), with no regular use of psychotropic medication in the last 6 months and 
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no use of alcohol in the 24 hours before testing. You should be willing to receive medical and psychiatric 
screening interviews; be willing for us to contact your GP prior to the commencement of the study, if 
necessary, about your medical history; and be willing to undergo a urine test for psychotropic compounds 
immediately prior to EEG testing. 
 
You will NOT be able to participate in the project, because it may involve an unacceptable risk to you, if you 
have: 
1. Susceptibility to photosensitivity. 
2. A history of seizure. 
3. A history of allergic skin reactions to chemical agents including detergents. 
 
If you participate, what will you be asked to do? 
For the main part of the test, we will record the electrical activity from your scalp, heart and a finger during a 
ten minute rest period and in a “stop signal” task with stimuli delivered on a computer screen and through 
earphones and to which you will make responses using a computer mouse. You will be interviewed about your 
physical and mental health and also be asked to complete several questionnaires that measure aspects of your 
mood and personality. The whole experiment will take about three hours. You will also be asked to return to 
the laboratory at 3 months and 6 months after your initial testing session at which time we will give you a brief 
interview to determine any changes in your anxiety-related symptoms, ask you to report on any treatment you 
have received since the initial testing session, and fill out some of the original questionnaires for a second 
time. These follow up tests are likely to take about one hour. In recognition of the time, inconvenience, and 
travel costs in attending for testing, you will be compensated at a rate of $15 for each hour of attendance at 
the end of each test period. 
 
Preparation for the experiment 
Hair products and natural oils on our scalp make it difficult to record your brain activities. It is important to us 
that you come with a clean scalp. Please avoid using any hair products on the day of the experiment.  We 
recommend that you wash your hair on the day or the day before and avoid using a hair conditioner. For 
participants with glasses, we also recommend that you wear contact lenses if possible for your own comfort.  
 
Electrical recording procedure 
You will put on an electro-cap as shown in the picture. We will fill the electrodes (small 
metal discs) attached to the cap with a gel that conducts brain signals from your scalp to 
our recording system. To achieve good recordings, we will abrade your skin gently before 
applying the gel. The electrodes are then connected to an amplifier that allows us to 
record your brain rhythms (EEG). We will also attach stick-on electrodes to your body to 
record your heart activity (ECG) and a clip on electrode to an index finger to measures 
your skin resistance/perspiration (GSR). The whole system is regularly tested and passes 
the current standards for connecting electrical equipment to people. 
 
Is there any risk of discomfort or harm from participation? 
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There is a risk of allergic skin reaction to the electrode gel and of minor discomfort from the abrasion of the 
skin surface during gel application. Exposure to stimuli on a computer screen has a rare risk of inducing 
seizures in those with or without a history of seizure. If you have a history either of photosensitivity or of any 
form of seizure you should not take part. The person running your electrical testing is required to be trained in 
the procedures for connecting you to the equipment and to have a current First Aid Certificate (with training 
renewed every two years by the New Zealand Red Cross) so that they can respond appropriately to any 
unexpected adverse events that occur during testing. 
 
What data will be collected, and how will they be used? 
Your physical and mental health status, questionnaire scores, and electrical recordings will be stored in secure 
computer databases and will be identified only with your participant number. Identifying data, including the 
identity of your GP, will be stored separately from the study data and will be used only for contact purposes. 
Any paper records will be stored securely in locked filing cabinets. Physical health status will be assessed only 
to exclude participants who do not meet the entry criteria. Mental health status will be assessed to allow 
exclusion of some conditions but, in particular, will be used to assess the classification of your anxiety disorder 
within the DSM diagnostic system. Your questionnaire, diagnostic and electrical data will be subjected to 
group statistical analysis to determine general group-wide personality trait relationships and differences from 
reference data. Urine samples, identified only by participant number, will be disposed of by the analysing 
laboratory using their usual procedures and only the qualitative, present/absent, result returned by the 
laboratory will be used for inclusion/exclusion. Data will be stored for 10 years and then deleted. 
 
What about anonymity and confidentiality? 
 
All information generated in this study will be considered highly confidential and must not be disclosed to any 
persons not directly concerned with the study. However, authorized regulatory officials and sponsor personnel 
will be allowed full access to the records. Only participant initials and unique participant study numbers will 
identify participants on data documents or in the database and identity data will be stored separately.  
However, participants’ full names may be made known to a regulatory agency or other authorized official (e.g. 
GP) if necessary. All data will be stored securely and accessed only by study personnel. Reporting of the 
completed research will be of aggregated data over all participants and no data will be reported linked to an 
individual participant number. 
 
Can Participants Change their Mind and Withdraw from the Project? 
You may withdraw from participation in the project at any time and without any disadvantage to yourself of any 
kind. 
What if Participants have any Questions? 
If you have any questions about our project, either now or in the future, please feel free to contact either:- 
Shabah Shadli (Telephone: 03 479 5835) or Professor Neil McNaughton (Telephone: 03 479 7634) 
shabah.shadli@otago.ac.nz   nmcn@psy.otago.ac.nz 
This project has been reviewed and approved by the University of Otago Human Ethics Committee (Health: H 15/005). If 
you have any concerns about the ethical conduct of the research you may contact the Committee through the Human 
Ethics Committee Administrator (ph 03 479-8256 or email gary.witte@otago.ac.n). Any issues you raise will be treated in 





Stop Signal EEG and Personality 
(Principal Investigator: Professor Neil McNaughton, Department of Psychology, 03-479 7634) 
CONSENT FORM FOR PARTICIPANTS 
1. I have read the Information Sheet concerning this study and understand the aims of this research 
project. 
2. I have had sufficient time to talk with other people of my choice about participating in the study.   
3. I confirm that I meet the criteria for participation which are explained in the Information Sheet. 
4. All my questions about the project have been answered to my satisfaction, and I understand that 
I am free to request further information at any stage.  
5. I know that my participation in the project is entirely voluntary, and that I am free to withdraw 
from the project at any time without disadvantage. 
6. I am aware that undergraduate students will be present and will carry out some parts of the 
experiment. 
7. I know that as a participant I will undergo electrical (EEG/ECG/GSR) testing, physical and 
mental health screening, and a qualitative urine test for psychotropic drugs and complete 
questionnaires assessing emotion, as listed in the information sheet. I understand that I may 
decline to answer any interview or questionnaire question without disadvantage of any kind. 
8. I know that no personal identifying information will be included in the paper records and electronic files 
which represent the data from the project, and that these will be placed in secure storage and kept for at 
least ten years.  
9. I understand the nature and size of the risks of discomfort or harm that are explained in the Information 
Sheet, including the rare risk of computer screen-induced seizures. 
10. I understand that the results of the project may be published but my anonymity will be preserved 
and only group data reported. 
 
I agree to take part in this project. I agree that my GP can be contacted for information 
about my health and to receive health-related 
information about me from this project 
 
………………………………………………… ………………………………………………… 
   (Full name)      (GP name, location) 
 
.............................................................................    ............................... 
       (Signature of participant)       (Date) 
This project has been reviewed and approved by the University of Otago Human Ethics Committee (Health: H 15/005). If 
you have any concerns about the ethical conduct of the research you may contact the Committee through the Human 
Ethics Committee Administrator (ph 03 479-8256 or email gary.witte@otago.ac.n). Any issues you raise will be treated in 
confidence and investigated and you will be informed of the outcome. 
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Appendix C – Missing trial data replacement code.  
%%% THIS CODE USES A LEAST SQUARED ERROR LINEAR INTERPOLATION METHOD TO 
REPLACE 
%%% MISSING RAW TRIAL DATA IN NON-PATIENT AND PATIENT SAMPLES RESPECTIVELY.  
%%% THIS EXAMPLE CODE IS WRITTEN FOR NON-PATIENTS. PATIENT CODE IS 
IDENTICAL 
%%% EXCEPT THAT PATIENT DATASETS ARE LOADED AT THE BEGINNING IN PLACE OF 
%%% NON-PATIENT DATASETS. 
%%%  
%%% THIS CODE LOADS STOP AND GO TRIAL DATASETS OF 33 TRIALS x 27 
%%% FREQUENCIES (SHORT SSD 4 - 12 Hz, MEDIUM SSD 4 - 12Hz, & LONG SSD 4 - 
%%% 12Hz) x 79 NON-PATIENTS(49 IN THE CASE OF PATIENTS). ANY SINGLE TRIAL 
MAY  
%%% BE MISSING DATA. IF A TRIAL IS MISSING DATA, ALL 9 FREQUENCIES WILL BE 
MISSING DATA.  
%%%  
%%% WRITTEN BY BEDE BYERS FOR USE IN HIS MSc THESIS, 10/07/2018. CODE IS 
%%% AVAILABLE FOR ACADEMIC USE OR MODIFICATION WITHOUT PRIOR PERMISSION OF 
THE AUTHOR.  
  




load('GCSR_stop_raw');    %%% LOAD RAW DATA FOR MISSING DATA REPLACEMENT. 
load('GCSR_go_raw'); 
  
both_trial_types_all_data = {GCSR_stop_raw,GCSR_go_raw};  %%% CREATE MASTER 
DATASET AND INDEX FOR MISSING TRIALS.  
file_zero_index = [];                                     %%% ESTABLISH 
FILE SIZE CONSTANTS -> NUM_TRIALS ... ETC 
[num_trials,num_collumns,num_files] = size(both_trial_types_all_data{1,2});  
  
%%% CODE ISOLATES EACH INDIVIDUAL'S LIST OF TRIALS BASED ON TRIAL TYPE AND 
SSD. 
%%% THEN INDEXS AND REMOVES MISSING DATA FROM THE DATASET SO AS TO PROVIDE 
%%% A DATASET FROM WHICH TO DRAW THE ADJACENT TRIALS TO DO THE 
%%% INTERPOLATION WITH. FINALLY CALCULATES THE NUMBER OF MISSING ZEROS. 
  
for data_type = 1:2                       
    for this_file = 1:num_files          
        current_file = 
both_trial_types_all_data{1,data_type}(:,:,this_file); 
        for SSD = 1:3                     
        SSD_all_channels_data = current_file(:,9*SSD-8:9*SSD);  
        rows_to_delete_idx = zeros(33,1);  
        for row_delete = 1:num_trials 
            if SSD_all_channels_data(row_delete,5)==0  %%% USING 8Hz AS A 
CHECK FOR MISSING TRIAL DATA. 
                rows_to_delete_idx(row_delete) = 1; 
            end     
        end 
        rows_to_delete_idx = logical(rows_to_delete_idx); 
        SSD_all_channels_excluding_missing = SSD_all_channels_data;  
        SSD_all_channels_excluding_missing(rows_to_delete_idx,:) = []; %%% 
SET OF EXTANT DATA. 
        SSD_all_channels_excluding_missing_index = 1:1:33; 
        
SSD_all_channels_excluding_missing_index(SSD_all_channels_data(:,5)==0) = 
[]; %%% INDEX OF EXTANT DATA. 
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        file_zero_index = find(~current_file(:,(-4+9*SSD)));%%% GENERATE 
MISSING DATA INDEX.  
        [num_zeros,~] = size(file_zero_index); %%% ASCERTAIN NUMBER OF 
MISSING TRIALS FOR THIS INDIVIDUALS' SSD.  
  
%%% IF PARTICIPANT IS MISSING 17 OR MORE TRIALS FOR ANY INDIVIDUAL SSD, 
%%% THEY ARE REMOVED FROM THE SAMPLE.  
         
        if num_zeros > 16 
            current_file(:,((9*SSD)-3):(9*SSD)) = NaN; 
        else     
         
%%% FOR EACH CHANNEL, 4 - 12 Hz, CONSTRUCT INDIVIDUAL VERSIONS OF THE 
EXTANT DATA  
%%% AND ITS INDEX, AND THE MISSING DATA INDEX. 
             
            for channel = 1:9 
            channel_data_full = SSD_all_channels_data(:,channel); 
            channel_data_excl_missing = 
SSD_all_channels_excluding_missing(:,channel); 
            channel_data_excl_missing_index = 
SSD_all_channels_excluding_missing_index; 
            channel_zero_index = file_zero_index; 
            num_channel_zeros = num_zeros; 
            num_writes = 0;        
            writing_points = []; 
            writing_length = [];  
             
%%% FOR EACH MISSING DATA POINT DETECT WHETHER IT IS A SOLITARY MISSING 
%%% DATA POINT, OR THERE ARE MULTIPLE CONSECUTIVE MISSING DATA POINTS. THEN 
%%% TRACK THE POSITION OF MISSING DATA (WRITING POINTS) AND LENGTH OF 
%%% MISSING DATA (WRITIGN LENGTH). 
             
            while ~isempty(channel_zero_index) 
            str_of_zeros = 1; 
            channel_zero_index(end+1) = 0; 
             
            for zero_index_item = 1:num_channel_zeros 
                if channel_zero_index(zero_index_item)+1 ~= 
channel_zero_index(zero_index_item+1) 
                    length_of_str = str_of_zeros; 
                    num_writes = num_writes + 1; 
                    break 
                else 
                    str_of_zeros = str_of_zeros + 1; 
                end 
            end 
  
            writing_points(num_writes) = channel_zero_index(1); 
            writing_length(num_writes) = length_of_str; 
            channel_zero_index(end) = []; 
            for del = 1:length_of_str 
            channel_zero_index(1) = []; 
            end 
            [num_channel_zeros,~] = size(channel_zero_index); 
            end 
            [~,num_points] = size(writing_points); 
  
%%% USE WRITING VECTORS TO MAKE INTERPOLATION VECTORS OF 6 + LENGTH OF THE  
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%%% MISSING DATA POINT. CASES ARE THEN SPLIT INTO INTERP AND EXTRAP CASES. 
%%% EXTRAP CASES OCCUR WHEN THE FIRST OR LAST DATA POINT IS MISSING.  
    
            for point = 1:num_points  
                greater_than = sum(double(channel_data_excl_missing_index > 
writing_points(point) + writing_length(point) - 1)); 
                less_than = sum(double(channel_data_excl_missing_index < 
writing_points(point))); 
                points_prior = ceil((writing_length(point) + 6) / 2); 
                points_post =  floor((writing_length(point) + 6) / 2); 
                yaxis = nan(writing_length(point) +6,1); 
                xaxis = yaxis; 
                xquery = nan(writing_length(point),1);   
%%% SPLIT CASES INTO EXTRAP AND INTERP  
                if greater_than == 0 || less_than == 0   
%%% SPLIT EXTRAP CASES INTO BEGINNING OR END OF SEQUENCE 
                    if greater_than == 0 
                        yaxis(1:writing_length(point) + 6,1) = 
channel_data_excl_missing(end - (writing_length(point) + 5):end,1); 
                        xaxis(1:writing_length(point) + 6,1) = 
channel_data_excl_missing_index(1,end - (writing_length(point) + 5):end); 
                    else  
                        yaxis(1:writing_length(point) + 6,1) = 
channel_data_excl_missing(1:(writing_length(point) + 6),1); 
                        xaxis(1:writing_length(point) + 6,1) = 
channel_data_excl_missing_index(1,1:(writing_length(point) + 6)); 
                    end 
                else 
%%%  ARRANGE CASES FOR INTERP - NO SPLITTING.             
                    while points_prior > less_than 
                        points_prior = points_prior - 1; 
                        points_post = points_post + 1; 
                    end     
                    while points_post > greater_than 
                        points_post = points_post - 1; 
                        points_prior = points_prior + 1; 
                    end  
                    initial_point = find(channel_data_excl_missing_index == 
(writing_points(point)-1)) - (points_prior-1); 
                    last_point = find(channel_data_excl_missing_index == 
(writing_points(point) + writing_length(point))) + points_post - 1; 
                    yaxis(1:writing_length(point) + 6,1) = 
channel_data_excl_missing(initial_point:last_point,1); 
                    xaxis(1:writing_length(point) + 6,1) = 
channel_data_excl_missing_index(1,initial_point:last_point); 
                end 
            for xq = 1:writing_length(point) 
                xquery(xq) = writing_points(point) + xq - 1; 
            end 
%%% SPLIT INTO EXTRAP AND INTERP CASES FOR YQUERY 
            Xaxis = [ones(length(xaxis),1) xaxis];  
            slope = Xaxis\yaxis; 
            yquery = slope(1) + xquery * slope(2);   
            current_file(xquery,9*(SSD - 1) + channel) = yquery; 
            end 
%%% WRITE UPDATED CURRENT FILE BACK INTO ORIGINAL DATASET 
            end 
        end 
        end 




    end 
        
end 
             
GCSR_stop_interp = both_trial_types_all_data{1,1};  
GCSR_go_interp = both_trial_types_all_data{1,2};  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
